,Unnamed: 0,Unnamed: 0.1,Drug,Chemical Structure,Adverse Effect / Toxicity,Species,Dose,Dose Type,Route,Source,Source Link,Year
0,1,1,Abiraterone Acetate,CC(=O)OC1CCC2(C)C(=CCC3C2CCC2(C)C(C4=CN=CC=C4)=CCC32)C1,Liver disorder,Rat,-2.6368220975871743,Repeated,Oral,"FDA approval package document: Pharmacology Review 202379/S-000 Part 05, page:2 PDF 431k",https://www.pharmapendium.com/browse/fda/Abiraterone Acetate/36da6c1c785b06cb275afd90d3ae3c24?reference=2,2011.0
1,2,4,Acalabrutinib,CC#CC(=O)N1CCCC1C1=NC(C2=CC=C(C(=O)NC3=NC=CC=C3)C=C2)=C2C(N)=NC=CN12,Liver disorder,Rat,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 210259/S-006; 210259/S-007 Part 11, page:19 PDF 824k",https://www.pharmapendium.com/browse/fda/Acalabrutinib/867e5c9b54eb25c785f393945bce36fa?reference=19,2019.0
2,3,5,Acamprosate Calcium,CC(=O)NCCCS(=O)(=O)O,Liver disorder,Mouse,-3.1760912590556813,Repeated,Oral,"FDA approval package document: Pharmacology Review 021431/S-000 Part 03, page:6 PDF 1998k",https://www.pharmapendium.com/browse/fda/Acamprosate Calcium/2e91376ec6c3cd0b7dabe48431bccc8c?reference=6,2004.0
3,4,9,Acarbose,CC1OC(OC2C(CO)OC(OC3C(CO)OC(O)C(O)C3O)C(O)C2O)C(O)C(O)C1NC1C=C(CO)C(O)C(O)C1O,Liver disorder,Rat,-2.164352855784437,Repeated,Oral,"FDA approval package document: Approval Package 020482/S-007, S-008, page:32 PDF 2313k",https://www.pharmapendium.com/browse/fda/Acarbose/00e46b9f65aa9d25f52c8473988cb9ad?reference=32,1998.0
4,5,11,Acetaminophen,CC(=O)NC1=CC=C(O)C=C1,Liver disorder,Rat,-3.02368179886074,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 2004779229   ---   DOI:10.1021/acs.chemrestox.9b00392   ISSN:0893-228X   JOURNAL:Chemical Research in Toxicology   PAGES:522   VOLUME:33,http://dx.doi.org/10.1021/acs.chemrestox.9b00392,2020.0
5,6,36,Aclidinium Bromide,O=C(OC1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)C(O)(C1=CC=CS1)C1=CC=CS1,Liver disorder,Rat,-7.92427928812995,Repeated,Inhalation,"FDA approval package document: Pharmacology Review 202450/S-000 Part 06, page:93 PDF 15689k",https://www.pharmapendium.com/browse/fda/Aclidinium Bromide/b314c7c42e68103349050f55e75f335c?reference=93,2011.0
6,7,41,Acyclovir,NC1=NC(=O)C2=C(N1)N(COCCO)C=N2,Liver disorder,Rat,-2.204119982655925,Repeated,Intraperitoneal,"FDA approval package document: Approval Package 018828/S-001, S-003, S-007 Part 01, page:16 PDF 5164k",https://www.pharmapendium.com/browse/fda/Acyclovir/13cd219c4e45594d1baa0e0a43d7f7b9?reference=16,1980.0
7,8,44,Adapalene,COC1=CC=C(C2=CC3=CC=C(C(=O)O)C=C3C=C2)C=C1C12CC3CC(CC(C3)C1)C2,Liver disorder,Rat,-0.7781512503836436,Repeated,Skin,"FDA approval package document: Pharmacology Review 021753/S-000, page:34 PDF 3426k",https://www.pharmapendium.com/browse/fda/Adapalene/81bf08dba0dcd3d1b56f5a8b75218a87?reference=34,2004.0
8,9,45,Adefovir Dipivoxil,CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C,Liver disorder,Mouse,-2.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 021449/S-000 Part 02, page:23 PDF 1491k",https://www.pharmapendium.com/browse/fda/Adefovir Dipivoxil/685c602c1039816622659807e0912f04?reference=23,2002.0
9,10,46,Ademetionine,C[S+](CCC(N)C(=O)[O-])CC1OC(N2C=NC3=C2N=CN=C3N)C(O)C1O,Liver disorder,Rat,-0.6020599913279624,Repeated,Subcutaneous,"Reference from PharmaPendium Published Toxicity: Toxicology 200,21,2004   ---   DOI:10.1016/J.TOX.2004.02.030   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:21   VOLUME:200",http://dx.doi.org/10.1016/J.TOX.2004.02.030,2004.0
10,12,49,Albendazole,CCCSC1=CC2=C(C=C1)NC(NC(=O)OC)=N2,Liver disorder,Rat,-0.4771212547196624,Repeated,Intraperitoneal,"Reference from PharmaPendium Published Toxicity: Environmental Toxicology and Pharmacology 9,31,2000   ---   DOI:10.1016/S1382-6689(00)00059-4   ISSN:1382-6689   JOURNAL:Environmental Toxicology and Pharmacology   PAGES:31   VOLUME:9",http://dx.doi.org/10.1016/S1382-6689(00)00059-4,2000.0
11,14,53,Alcohol,CCO,Liver disorder,Rat,-5.696590845287982,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: 362085967   ---   DOI:10.1111/j.1472-8206.2010.00861.x   ISSN:0767-3981   JOURNAL:Fundamental and Clinical Pharmacology   PAGES:493   VOLUME:25,http://dx.doi.org/10.1111/j.1472-8206.2010.00861.x,2011.0
12,15,96,Alectinib Hydrochloride,CCC1=CC2=C(C=C1N1CCC(N3CCOCC3)CC1)C(C)(C)C1=C(C2=O)C2=C(C=C(C#N)C=C2)N1,Liver disorder,Rat,-1.1613680022349748,Repeated,Oral,"FDA approval package document: Pharmacology Review 208434/S-000, page:140 PDF 18427k",https://www.pharmapendium.com/browse/fda/Alectinib Hydrochloride/58836d69022270b42fe1db46093ae15f?reference=140,2015.0
13,16,98,Alfuzosin Hydrochloride,COC1=CC2=NC(N(C)CCCNC(=O)C3CCCO3)=NC(N)=C2C=C1OC,Liver disorder,Rat,-2.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 021287/S-000 Part 01, page:43 PDF 1318k",https://www.pharmapendium.com/browse/fda/Alfuzosin Hydrochloride/e0725d4b1356803a41d34119e5da56f6?reference=43,2003.0
14,17,99,Aliskiren Hemifumarate,COCCCOC1=C(OC)C=CC(CC(CC(N)C(O)CC(C(=O)NCC(C)(C)C(N)=O)C(C)C)C(C)C)=C1,Liver disorder,Rat,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Pharmacology Review 021985/S-000 Part 02, page:65 PDF 5830k",https://www.pharmapendium.com/browse/fda/Aliskiren Hemifumarate/fd0a434195f39a82aca9da1103e97ffb?reference=65,2007.0
15,18,100,Alitretinoin,CC(C=C/C=C(C)\C=C\C1=C(C)CCCC1(C)C)=CC(=O)O,Liver disorder,Rat,-0.0,Repeated,Oral,"EMA approval document: Scientific Discussion, page:4 PDF 802k",https://www.pharmapendium.com/browse/ema/Alitretinoin/35e2d050a2821eeeeb5df75b94b78b19?reference=4,2004.0
16,19,101,Allopurinol,O=C1NC=NC2=C1C=NN2,Liver disorder,Mouse,-0.4771212547196624,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Biological and Pharmaceutical Bulletin (Tokyo 150, Japan) 30,1551,2007   ---   DOI:10.1248/BPB.30.1551   JOURNAL:Biological and Pharmaceutical Bulletin   PAGES:1551   VOLUME:30",http://dx.doi.org/10.1248/BPB.30.1551,2007.0
17,20,102,Almotriptan Malate,CN(C)CCC1=CNC2=C1C=C(CS(=O)(=O)N1CCCC1)C=C2,Liver disorder,Rat,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Pharmacology Review 021001/S-000 Part 01, page:15 PDF 1950k",https://www.pharmapendium.com/browse/fda/Almotriptan Malate/65a4fd1f91a6b2d9de68e8285c53b339?reference=15,1997.0
18,21,104,Alogliptin Benzoate,CN1C(=O)C=C(N2CCCC(N)C2)N(CC2=C(C#N)C=CC=C2)C1=O,Liver disorder,Rat,-3.014205413953746,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/207780/2013; EMEA/H/C/002182/0000, page:21 PDF 1425k",https://www.pharmapendium.com/browse/ema/Alogliptin Benzoate/aaa83508c16f9bd37e0b093390ff83e5?reference=21,2013.0
19,24,121,Amdinocillin,CC1(C)SC2C(/N=C/N3CCCCCC3)C(=O)N2C1C(=O)O,Liver disorder,Rat,-4.116441697539312,Repeated,,"Reference from PharmaPendium Published Toxicity: Eksperimental'naya i Klinicheskaya Farmakoterapiya 9,91,1980   ---   ISSN:0367-0589   JOURNAL:Eksperimental'naya i Klinicheskaya Farmakoterapiya   PAGES:91   VOLUME:9",,1980.0
20,25,123,Amifampridine,NC1=CC=NC=C1N,Liver disorder,Rat,-1.568201724066995,Repeated,Oral,"FDA approval package document: Pharmacology Review 020932/S-000, page:26 PDF 9788k",https://www.pharmapendium.com/browse/fda/Amifampridine/8fae6984103cb80815b863ccaae6a548?reference=26,2019.0
21,26,128,Amifampridine Phosphate,NC1=C(N)C=NC=C1,Liver disorder,Mouse,-1.568201724066995,Repeated,Oral,"FDA approval package document: Pharmacology Review 020932/S-000, page:22 PDF 9788k",https://www.pharmapendium.com/browse/fda/Amifampridine Phosphate/8fae6984103cb80815b863ccaae6a548?reference=22,2019.0
22,27,133,Amikacin Sulfate,NCCC(O)C(=O)NC1CC(N)C(OC2OC(CN)C(O)C(O)C2O)C(O)C1OC1OC(CO)C(O)C(N)C1O,Liver disorder,Rat,-1.146128035678238,Repeated,Intramuscular,Reference from PharmaPendium Published Toxicity: 362609954   ---   ISSN:1827-8620   JOURNAL:Pharmacologyonline   PAGES:451   VOLUME:2,,2011.0
23,28,134,Aminoglutethimide,CCC1(C2=CC=C(N)C=C2)CCC(=O)NC1=O,Liver disorder,Rat,-1.7745169657285496,Repeated,Oral,"FDA approval package document: Approval Package 018202/S-014 Part 01, page:26 PDF 4351k",https://www.pharmapendium.com/browse/fda/Aminoglutethimide/261e6bcd70ef7293ed647d32e5e8ca20?reference=26,1979.0
24,29,138,Amiodarone Hydrochloride,CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1,Liver disorder,Rat,-1.4825162866063686,Repeated,Unreported,"FDA approval package document: Approval Package 018972/S-014 Part 13, page:36 PDF 4900k",https://www.pharmapendium.com/browse/fda/Amiodarone Hydrochloride/f4944cf744f11785c20123f7038cc342?reference=36,1983.0
25,30,146,Amisulpride,CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC,Liver disorder,Rat,-1.0,Repeated,Intravenous,"FDA approval package document: Approval Package 209510/S-000 Part 05, page:31 PDF 1020k",https://www.pharmapendium.com/browse/fda/Amisulpride/2f496958625a36ff59ac65f88cc2dc87?reference=31,2018.0
26,31,147,Amitriptyline Hydrochloride,CN(C)CCC=C1C2=C(C=CC=C2)CCC2=C1C=CC=C2,Liver disorder,Rat,-1.0280287236002437,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: 2005119040   ---   DOI:10.1016/j.toxlet.2020.02.007   ISSN:0378-4274   JOURNAL:Toxicology Letters   PAGES:43   VOLUME:325,http://dx.doi.org/10.1016/j.toxlet.2020.02.007,2020.0
27,33,152,Ammonium Sulfate,O=S(=O)(O)O,Liver disorder,Rat,-0.8450980400142568,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 368838235   ---   ISSN:0975-6299   JOURNAL:International Journal of Pharma and Bio Sciences   VOLUME:4,,2013.0
28,35,155,Amphotericin B,CC1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/C(OC2OC(C)C(O)C(N)C2O)CC2OC(O)(CC(O)CC(O)C(O)CCC(O)CC(O)CC(=O)OC(C)C(C)C1O)CC(O)C2C(=O)O,Liver disorder,Rat,-1.0,Repeated,Intravenous,"FDA approval package document: Approval Package 050724 Part 02, page:67 PDF 5905k",https://www.pharmapendium.com/browse/fda/Amphotericin B/a0fb7f56d6dd1ca570987dce7397b902?reference=67,1995.0
29,37,160,Ampicillin,CC1(C)SC2C(NC(=O)C(N)C3=CC=CC=C3)C(=O)N2C1C(=O)O,Liver disorder,Rat,-0.4771212547196624,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: 610250096   ---   DOI:10.4314/tjpr.v15i4.6   ISSN:1596-5996   JOURNAL:Tropical Journal of Pharmaceutical Research   PAGES:709   VOLUME:15,http://dx.doi.org/10.4314/tjpr.v15i4.6,2016.0
30,38,161,Anesthetic Ether,CCOCC,Liver disorder,Rat,-1.954242509439325,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: U.S. Environmental Protection Agency; High Production Volume (HPV) Challenge; Ethane,1,1'-oxybis-.pdf (http://www.epa.gov/HPV/pubs/summaries/viewsrch.htm) -,-,2003   ---   JOURNAL:US EPA, HPV (http://www.epa.gov/hpv/pubs/summaries/eth11oxy/c15001tc.htm)",,2003.0
31,39,162,Anidulafungin,CCCCCOC1=CC=C(C2=CC=C(C3=CC=C(C(=O)NC4CC(O)C(O)NC(=O)C5C(O)C(C)CN5C(=O)C(C(C)O)NC(=O)C(C(O)C(O)C5=CC=C(O)C=C5)NC(=O)C5CC(O)CN5C(=O)C(C(C)O)NC4=O)C=C3)C=C2)C=C1,Liver disorder,Rat,-1.6766936096248666,Repeated,Intravenous,"EMA approval document: Scientific Discussion, page:7 PDF 244k",https://www.pharmapendium.com/browse/ema/Anidulafungin/78c7472ed35b0e6fd66deb769a7501a5?reference=7,2007.0
32,42,171,Apremilast,CCOC1=C(OC)C=CC(C(CS(C)(=O)=O)N2C(=O)C3=CC=CC(NC(C)=O)=C3C2=O)=C1,Liver disorder,Mouse,-2.740362689494244,Repeated,Oral,"FDA approval package document: Pharmacology Review 205437/S-000 Part 04, page:24 PDF 15043k",https://www.pharmapendium.com/browse/fda/Apremilast/640f8cdc51359cc04d02fbdc43b32379?reference=24,2014.0
33,44,178,Arformoterol Tartrate,COC1=CC=C(CC(C)NCC(O)C2=CC=C(O)C(NC=O)=C2)C=C1,Liver disorder,Mouse,-6.875061408156503,Repeated,Oral,"FDA approval package document: Pharmacology Review 021912/S-000 Part 05, page:57 PDF 6862k",https://www.pharmapendium.com/browse/fda/Arformoterol Tartrate/d86103401d474f47d32ccc716b372604?reference=57,2006.0
34,46,207,Armodafinil,NC(=O)C[S+]([O-])C(C1=CC=CC=C1)C1=CC=CC=C1,Liver disorder,Rat,-2.12057393120585,Repeated,Oral,"FDA approval package document: Pharmacology Review 021875/S-000, page:51 PDF 4896k",https://www.pharmapendium.com/browse/fda/Armodafinil/2021a1eaa664af7eee35442a36027c5f?reference=51,2006.0
35,47,216,Artemether,COC1OC2OC3(C)CCC4C(C)CCC(C1C)C24OO3,Liver disorder,Rat,-1.3222192947339193,Repeated,Intragastric,"Reference from PharmaPendium Published Toxicity: 368722011   ---   DOI:10.1002/bdrb.21054   ISSN:1542-9733   JOURNAL:Birth Defects Research. Part B, Developmental and Reproductive Toxicology   PAGES:183   VOLUME:98",http://dx.doi.org/10.1002/bdrb.21054,2013.0
36,48,218,Artesunate,CC1CCC2C(C)C(OC(=O)CCC(=O)O)OC3OC4(C)CCC1C32OO4,Liver disorder,Mouse,-1.2471546148811268,Repeated,Unreported,Reference from PharmaPendium Published Toxicity: 605203129   ---   DOI:10.1016/j.mrgentox.2014.11.001   ISSN:1383-5718   JOURNAL:Mutation Research - Genetic Toxicology and Environmental Mutagenesis   PAGES:1   VOLUME:777,http://dx.doi.org/10.1016/j.mrgentox.2014.11.001,2015.0
37,49,221,Ascorbic Acid,OCC(O)C1=C(O)C(O)=C(O)O1,Liver disorder,Rat,-1.5314789170422551,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicology 188,117,2003   ---   DOI:10.1016/S0300-483X(03)00056-8   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:117   VOLUME:188",http://dx.doi.org/10.1016/S0300-483X(03)00056-8,2003.0
38,50,224,Aspirin,CC(=O)OC1=CC=CC=C1C(=O)O,Liver disorder,Rat,-1.0253058652647702,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 52991863   ---   DOI:10.1016/j.biomag.2014.01.004   ISSN:2210-5220   JOURNAL:Biomedicine and Aging Pathology   PAGES:137   VOLUME:4,http://dx.doi.org/10.1016/j.biomag.2014.01.004,2014.0
39,52,230,Atazanavir Sulfate,COC(=O)NC(C(=O)NC(CC1=CC=CC=C1)C(O)CN(CC1=CC=C(C2=NC=CC=C2)C=C1)NC(=O)C(NC(=O)OC)C(C)(C)C)C(C)(C)C,Liver disorder,Mouse,-2.5921767573958667,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologist 44,363,2005   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:363   VOLUME:44",,2005.0
40,55,244,Atropine Sulfate,CN1C2CCC1CC(OC(=O)C(CO)C1=CC=CC=C1)C2,Liver disorder,Rat,-1.235528446907549,Repeated,Intraperitoneal,"FDA approval package document: Pharmacology Review 206289/S-000 Part 04, page:17 PDF 382k",https://www.pharmapendium.com/browse/fda/Atropine Sulfate/2a2c7a74cc4a926793accbc4aed29a5f?reference=17,2013.0
41,58,264,Avobenzone,COC1=CC=C(C(=O)CC(=O)C2=CC=C(C(C)(C)C)C=C2)C=C1,Liver disorder,Rat,-3.0,Repeated,Oral,"FDA approval package document: Review 020045, page:13 PDF 640k",https://www.pharmapendium.com/browse/fda/Avobenzone/1ba0ad145918a8be8f01db0fb944c3e2?reference=13,1987.0
42,59,265,Axitinib,CNC(=O)C1=C(SC2=CC3=NNC(C=CC4=NC=CC=C4)=C3C=C2)C=CC=C1,Liver disorder,Mouse,-1.9420080530223127,Repeated,Oral,"FDA approval package document: Pharmacology Review 202324/S-000 Part 06, page:7 PDF 382k",https://www.pharmapendium.com/browse/fda/Axitinib/3e8dfc89220ddd11838bc9d1d2dc703d?reference=7,2012.0
43,60,267,Azathioprine,CN1C=NC([N+](=O)[O-])=C1SC1=NC=NC2=C1N=CN2,Liver disorder,Mouse,-0.7781512503836436,Repeated,Oral,Reference from PharmaPendium Published Toxicity: E-370330890   ---   DOI:10.1016/j.toxlet.2013.10.025   ISSN:1879-3169   JOURNAL:Toxicology Letters   PAGES:215   VOLUME:224,http://dx.doi.org/10.1016/j.toxlet.2013.10.025,2014.0
44,62,271,Azilsartan Kamedoxomil,CCOC1=NC2=CC=CC(C(=O)OCC3=C(C)OC(=O)O3)=C2N1CC1=CC=C(C2=CC=CC=C2C2=NC(O)ON2)C=C1,Liver disorder,Rabbit,-1.3979400086720375,Repeated,Oral,"FDA approval package document: Pharmacology Review 200796/S-000 Part 02, page:40 PDF 5204k",https://www.pharmapendium.com/browse/fda/Azilsartan Kamedoxomil/5d997bf184c8cbfb579cc91fed19ad0c?reference=40,2010.0
45,63,273,Azithromycin,CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)CN(C)C(C)C(O)C1(C)O,Liver disorder,Mouse,-1.8893017025063104,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 2006942899   ---   DOI:10.1016/j.bcp.2020.114130   ISSN:0006-2952   JOURNAL:Biochemical Pharmacology   PAGES:114130   VOLUME:180,http://dx.doi.org/10.1016/j.bcp.2020.114130,2020.0
46,64,275,Aztreonam,CC1C(=NC(=O)C(NOC(C)(C)C(=O)O)C2=CSC(N)=N2)C(=O)N1S(=O)(=O)O,Liver disorder,Rat,-3.255272505103306,Repeated,Subcutaneous,"FDA approval package document: Approval Package 050580 Part 04, page:48 PDF 6472k",https://www.pharmapendium.com/browse/fda/Aztreonam/7b921af7cebff9f1cb6a52238d057819?reference=48,1986.0
47,66,280,Baricitinib,CCS(=O)(=O)N1CC(CC#N)(N2C=C(C3=C4C=CNC4=NC=N3)C=N2)C1,Liver disorder,Mouse,-1.8808135922807916,Repeated,Oral,"FDA approval package document: Pharmacology Review 207924/S-000 Part 23, page:2 PDF 381k",https://www.pharmapendium.com/browse/fda/Baricitinib/11bacd65f5b48bf3a4448a1c8063e8ac?reference=2,2016.0
48,69,291,Belinostat,O=S(=O)(NC1=CC=CC=C1)C1=CC(/C=C/C(O)=NO)=CC=C1,Liver disorder,Rat,-2.0,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 206256/S-000, page:77 PDF 11976k",https://www.pharmapendium.com/browse/fda/Belinostat/c77bbad74ba39672782a4458a4dd7e38?reference=77,2014.0
49,70,292,Bempedoic Acid,CC(C)(CCCCCC(O)CCCCCC(C)(C)C(=O)O)C(=O)O,Liver disorder,Rat,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 211616/S-000 Part 08, page:18 PDF 849k",https://www.pharmapendium.com/browse/fda/Bempedoic Acid/ab62f621ee1b630854d8da3ece6dda69?reference=18,2019.0
50,73,296,Benznidazole,O=C(CN1C=CN=C1[N+](=O)[O-])NCC1=CC=CC=C1,Liver disorder,Rabbit,-1.213074825308851,Repeated,Oral,"FDA approval package document: Pharmacology Review 209570/S-000 Part 01, page:90 PDF 11345k",https://www.pharmapendium.com/browse/fda/Benznidazole/ea6c524b79d1ed8cd262a8adc8124792?reference=90,2017.0
51,74,299,Benzophenone,O=C(C1=CC=CC=C1)C1=CC=CC=C1,Liver disorder,Rat,-0.4771212547196624,Repeated,Intraperitoneal,"Reference from PharmaPendium Published Toxicity: Toxicology and Applied Pharmacology 193,66,2003   ---   DOI:10.1016/J.TAAP.2003.08.001   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:66   VOLUME:193",http://dx.doi.org/10.1016/J.TAAP.2003.08.001,2003.0
52,75,301,Benzoyl Peroxide,O=C(OOC(=O)C1=CC=CC=C1)C1=CC=CC=C1,Liver disorder,Mouse,-1.6232492903979006,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 51362382   ---   DOI:10.1016/j.etap.2011.03.009   ISSN:1382-6689   JOURNAL:Environmental Toxicology and Pharmacology   PAGES:479   VOLUME:31,http://dx.doi.org/10.1016/j.etap.2011.03.009,2011.0
53,76,302,Benzylpenicillin,CC1(C)SC2C(NC(=O)CC3=CC=CC=C3)C(=O)N2C1C(=O)O,Liver disorder,Mouse,-0.7781512503836436,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 2000792357   ---   DOI:10.1016/j.chemosphere.2018.03.066   ISSN:0045-6535   JOURNAL:Chemosphere   PAGES:757   VOLUME:202,http://dx.doi.org/10.1016/j.chemosphere.2018.03.066,2018.0
54,78,304,"Betaine, Anhydrous",C[N+](C)(C)CC(=O)[O-],Liver disorder,Mouse,-1.146128035678238,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologist 44,393,2005   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:393   VOLUME:44",,2005.0
55,82,312,Bexarotene,C=C(C1=CC=C(C(=O)O)C=C1)C1=C(C)C=C2C(=C1)C(C)(C)CCC2(C)C,Liver disorder,Mouse,-0.9030899869919436,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 607343759   ---   DOI:10.1016/j.expneurol.2015.12.003   ISSN:0014-4886   JOURNAL:Experimental Neurology   PAGES:1   VOLUME:277,http://dx.doi.org/10.1016/j.expneurol.2015.12.003,2016.0
56,86,321,Bisoprolol Fumarate,CC(C)NCC(O)COC1=CC=C(COCCOC(C)C)C=C1,Liver disorder,Rat,-2.026328938722349,Repeated,Oral,"FDA approval package document: Approval Package 019982/S-001 Part 04, page:16 PDF 5638k",https://www.pharmapendium.com/browse/fda/Bisoprolol Fumarate/7c49937d2aea8b01f741768995f98fd7?reference=16,1992.0
57,87,325,Bleomycin Sulfate,CC1=C(C(=O)NC(C(=O)NC(C)C(O)C(C)C(=O)NC(C(=O)NCCC2=NC(C3=NC=C(C(N)=O)S3)=CS2)C(C)O)C(OC2OC(CO)C(O)C(O)C2OC2OC(CO)C(O)C(OC(N)=O)C2O)C2=CNC=N2)N=C(C(CC(N)=O)NCC(N)C(N)=O)N=C1N,Liver disorder,Rat,-0.6532125137753437,Repeated,Intraperitoneal,"FDA approval package document: Approval Package 050443 Part 01, page:27 PDF 3748k",https://www.pharmapendium.com/browse/fda/Bleomycin Sulfate/19bfc8f11930266e8d7842c8409c0fd8?reference=27,1973.0
58,88,327,Boceprevir,CC(C)(C)NC(=O)NC(C(=O)N1CC2C(C1C(=O)NC(CC1CCC1)C(=O)C(N)=O)C2(C)C)C(C)(C)C,Liver disorder,Mouse,-2.592916611888093,Repeated,Oral,"FDA approval package document: Pharmacology Review 202258/S-000 Part 02, page:8 PDF 902k",https://www.pharmapendium.com/browse/fda/Boceprevir/c5550a5ea2e47ac009239c204de63791?reference=8,2011.0
59,91,339,Bremelanotide Acetate,CCCCC(NC(C)=O)C(=O)NC1CC(=O)NCCCCC(C(=O)O)NC(=O)C(CC2=CNC3=C2C=CC=C3)NC(=O)C(CCCN=C(N)N)NC(=O)C(CC2=CC=CC=C2)NC(=O)C(CC2=CNC=N2)NC1=O,Liver disorder,Mouse,-1.8750612633917,Repeated,Subcutaneous,"FDA approval package document: Approval Package 210557/S-000 Part 09, page:20 PDF 9986k",https://www.pharmapendium.com/browse/fda/Bremelanotide Acetate/a8d65325f36d32fe8e0ad79ad1236cbf?reference=20,2018.0
60,92,341,Brexanolone,CC(=O)C1CCC2C3CCC4CC(O)CCC4(C)C3CCC12C,Liver disorder,Rabbit,-1.1760912590556811,Repeated,Intravenous,"FDA approval package document: Approval Package 211371/S-000 Part 02, page:45 PDF 10413k",https://www.pharmapendium.com/browse/fda/Brexanolone/04fcc70ce29c52cd3ab790307f20bf51?reference=45,2018.0
61,93,342,Brexpiprazole,O=C1C=CC2=CC=C(OCCCCN3CCN(C4=C5C=CSC5=CC=C4)CC3)C=C2N1,Liver disorder,Rabbit,-2.099384632135912,Repeated,Oral,"FDA approval package document: Pharmacology Review 205422/S-000 Part 03, page:52 PDF 7660k",https://www.pharmapendium.com/browse/fda/Brexpiprazole/70aee4e8a97fd2fdcdd25e7a34c3ff7a?reference=52,2014.0
62,95,351,Budesonide,CCCC1OC2CC3C4CC=C5CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1,Liver disorder,Rat,-8.0,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 205613/S-000, page:84 PDF 12388k",https://www.pharmapendium.com/browse/fda/Budesonide/bd4d8add95e11b989fedcf5e8aabeae7?reference=84,2014.0
63,96,352,Bumetanide,CCCCNC1=CC(C(=O)O)=CC(S(N)(=O)=O)=C1OC1=CC=CC=C1,Liver disorder,Rat,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Approval Package 018225; 018226 Part 04, page:17 PDF 4352k",https://www.pharmapendium.com/browse/fda/Bumetanide/7d3f083cc221761368a8417c279d49cb?reference=17,1994.0
64,97,353,Buprenorphine,COC12CCC3(CC1C(C)(O)C(C)(C)C)C1CC4=CC=C(O)C5=C4C3(CCN1CC1CC1)C2O5,Liver disorder,Rat,-0.8239087409443188,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 209819/S-000 Part 03, page:14 PDF 6208k",https://www.pharmapendium.com/browse/fda/Buprenorphine/21120bffdff35b6708127a237f1744af?reference=14,2017.0
65,100,362,Buspirone Hydrochloride,O=C1CC2(CCCC2)CC(=O)N1CCCCN1CCN(C2=NC=CC=N2)CC1,Liver disorder,Rat,-2.255272505103306,Repeated,Oral,"FDA approval package document: Approval Package 018731/S-025, S-027, S-031, S-018 Part 04, page:18 PDF 5249k",https://www.pharmapendium.com/browse/fda/Buspirone Hydrochloride/94a5c4d35026cb4c0ae15665ae80f77b?reference=18,1996.0
66,102,365,Cabazitaxel,COC1=C2C(C)C(OC(=O)C(O)C(NC(=O)OC(C)(C)C)C3=CC=CC=C3)CC(O)(C(OC(=O)C3=CC=CC=C3)C3C4(OC(C)=O)COC4CC(OC)C3(C)C1=O)C2(C)C,Liver disorder,Rat,-1.3424226808222062,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 201023/S-000 Part 09, page:13 PDF 479k",https://www.pharmapendium.com/browse/fda/Cabazitaxel/d9f8fae9f890d8ee63caaa73d80587d4?reference=13,2010.0
67,104,371,Calcitriol,C=C1/C(=C\C=C2/CCCC3(C)C2CCC3C(C)CCCC(C)(C)O)CC(O)CC1O,Liver disorder,Rat,-6.778151250383644,Repeated,Oral,"FDA approval package document: Approval Package 018874/S-001, S-002, S-007, S-004 Part 02, page:11 PDF 2088k",https://www.pharmapendium.com/browse/fda/Calcitriol/be29cce2768bc536723a07b269a43f84?reference=11,1986.0
68,105,372,Calcium Carbonate,O=C(O)O,Liver disorder,Rat,-1.6020599913279625,Repeated,Inhalation,"Reference from PharmaPendium Published Toxicity: Vrednie chemichescie veshestva. Neorganicheskie soedinenia elementov -,114,1988   ---   JOURNAL:Vrednie chemichescie veshestva. Neorganicheskie soedinenia elementov   PAGES:114",,1988.0
69,106,373,Calusterone,CC1C=C2CC(=O)CCC2(C)C2CCC3(C)C(CCC3(C)O)C12,Liver disorder,Rat,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 017383, page:13 PDF 1748k",https://www.pharmapendium.com/browse/fda/Calusterone/35f5b347bcccb9d59869e0791026e400?reference=13,1973.0
70,108,378,Cannabidiol,C=C(C)C1CCC(C)=CC1C1=C(O)C=C(CCCCC)C=C1O,Liver disorder,Rat,-1.845098040014257,Repeated,Oral,"FDA approval package document: Pharmacology Review 210365/S-000, page:74 PDF 12775k",https://www.pharmapendium.com/browse/fda/Cannabidiol/2ca6aedc4b850302e03713d2ab8b19aa?reference=74,2018.0
71,109,380,Capsaicin,COC1=CC(CNC(=O)CCCC/C=C/C(C)C)=CC=C1O,Liver disorder,Rat,-0.9030899869919436,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 364898980   ---   DOI:10.1177/0748233711413801   ISSN:0748-2337   JOURNAL:Toxicology and Industrial Health   PAGES:428   VOLUME:28,http://dx.doi.org/10.1177/0748233711413801,2012.0
72,110,381,Captopril,CC(CS)C(=O)N1CCCC1C(=O)O,Liver disorder,Rabbit,-2.096910013008056,Repeated,Oral,"FDA approval package document: Approval Package 018343/S-013, S-005, S-018 Part 03, page:52 PDF 3859k",https://www.pharmapendium.com/browse/fda/Captopril/c0cb9db38bbf2f3e3a59d01c6bea2f11?reference=52,1980.0
73,111,385,Carbamazepine,NC(=O)N1C2=CC=CC=C2C=CC2=CC=CC=C21,Liver disorder,Rat,-1.252853030979893,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 606078224   ---   DOI:10.1016/j.etp.2015.09.004   ISSN:0940-2993   JOURNAL:Experimental and Toxicologic Pathology   PAGES:27   VOLUME:68,http://dx.doi.org/10.1016/j.etp.2015.09.004,2016.0
74,112,395,Carbenoxolone,CC1(C(=O)O)CCC2(C)CCC3(C)C(=C2C1)CC(=O)C1C2(C)CCC(OC(=O)CCC(=O)O)C(C)(C)C2CCC13C,Liver disorder,Rat,-0.4771212547196624,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Journal of Pharmacology and Experimental Therapeutics 305,167,2003   ---   DOI:10.1124/JPET.102.044842   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:167   VOLUME:305",http://dx.doi.org/10.1124/JPET.102.044842,2003.0
75,113,396,Carbutamide,CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1,Liver disorder,Rat,-3.4771212547196626,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Carbutamide30   ---   JOURNAL:Canadian Medical Association Journal   PAGES:972   VOLUME:74,,1956.0
76,114,397,Carfilzomib,CC(C)CC(NC(=O)C(CCC1=CC=CC=C1)NC(=O)CN1CCOCC1)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CC(C)C)C(=O)C1(C)CO1,Liver disorder,Rat,-1.3424226808222062,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 202714/S-000 Part 04, page:44 PDF 11026k",https://www.pharmapendium.com/browse/fda/Carfilzomib/1edacd3d842dc9102583efb676c8d26c?reference=44,2012.0
77,115,401,Carisoprodol,CCCC(C)(COC(N)=O)COC(=O)NC(C)C,Liver disorder,Mouse,-2.271841606536499,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Carisoprodol2   ---   DOI:10.2307/3433446   JOURNAL:Environmental Health Perspectives   PAGES:283   VOLUME:105,http://dx.doi.org/10.2307/3433446,1997.0
78,117,405,Cefepime Hydrochloride,CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(C[N+]3(C)CCCC3)CSC12)C1=CSC(N)=N1,Liver disorder,Rat,-1.4471580313422192,Repeated,Intramuscular,Reference from PharmaPendium Published Toxicity: 363132402   ---   ISSN:0974-4304   JOURNAL:International Journal of PharmTech Research   PAGES:2149   VOLUME:3,,2011.0
79,118,406,Cefmetazole Sodium,COC1(NC(=O)CSCC#N)C(=O)N2C(C(=O)O)=C(CSC3=NN=NN3C)CSC21,Liver disorder,Rat,-3.1356626020000733,Repeated,Subcutaneous,"FDA approval package document: Approval Package 050637 Part 05, page:22 PDF 4969k",https://www.pharmapendium.com/browse/fda/Cefmetazole Sodium/18f8332e5006455f280d01ed6e93044a?reference=22,1989.0
80,119,409,Cefotaxime Sodium,CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(COC(C)=O)CSC12)C1=CSC(N)=N1,Liver disorder,Rat,-3.0,Repeated,Intravenous,"FDA approval package document: Approval Package 050547 Part 05, page:7 PDF 6591k",https://www.pharmapendium.com/browse/fda/Cefotaxime Sodium/197bcdf0b500cc4236bc475a0613d6fe?reference=7,1981.0
81,120,411,Cefpodoxime Proxetil,COC=C1CSC2C(=NC(=O)C(NOC)C3=CSC(N)=N3)C(=O)N2C1C(=O)OC(C)OC(=O)OC(C)C,Liver disorder,Rat,-2.4771212547196626,Repeated,Intravenous,"FDA approval package document: Approval Package 050674 Part 08, page:8 PDF 5717k",https://www.pharmapendium.com/browse/fda/Cefpodoxime Proxetil/e6e1755a712ed6911a08fce6785756ee?reference=8,1992.0
82,121,412,Cefprozil,CC=CC1=C(C(=O)O)N2C(=O)C(NC(=O)C(N)C3=CC=C(O)C=C3)C2SC1,Liver disorder,Rat,-3.3152704347785917,Repeated,Oral,"FDA approval package document: Approval Package 050664 Part 01, page:56 PDF 5362k",https://www.pharmapendium.com/browse/fda/Cefprozil/e560a1134cc0366ae7cd902e80fdf30d?reference=56,1991.0
83,122,415,Ceftazidime,CC(C)(ON=C(C(=O)NC1C(=O)N2C(C(=O)[O-])=C(C[N+]3=CC=CC=C3)CSC12)C1=CSC(N)=N1)C(=O)O,Liver disorder,Rat,-3.8846065812979305,Repeated,Subcutaneous,"FDA approval package document: Approval Package 050578 Part 01, page:16 PDF 4762k",https://www.pharmapendium.com/browse/fda/Ceftazidime/1cd0911cf52fca25f2dc0e6329639eec?reference=16,1985.0
84,123,418,Ceftriaxone Sodium,CON=C(C(=O)NC1C(=O)N2C(C(=O)O)=C(CSC3=NC(=O)C(=O)NN3C)CSC12)C1=CSC(N)=N1,Liver disorder,Rat,-2.096910013008056,Repeated,Intravenous,"FDA approval package document: Approval Package 050585 Part 07, page:14 PDF 6291k",https://www.pharmapendium.com/browse/fda/Ceftriaxone Sodium/5611a3c3215e7ebc46085bb5ccdea702?reference=14,1984.0
85,124,419,Cefuroxime Axetil,CON=C(C(=O)NC1C(=O)N2C(C(=O)OC(C)OC(C)=O)=C(COC(N)=O)CSC12)C1=CC=CO1,Liver disorder,Rat,-3.0,Repeated,Oral,"FDA approval package document: Approval Package 050605 Part 16, page:27 PDF 4639k",https://www.pharmapendium.com/browse/fda/Cefuroxime Axetil/b25f6a410dc2974185b17d77920da24d?reference=27,1985.0
86,128,423,Chenodiol,CC(CCC(=O)O)C1CCC2C3C(O)CC4CC(O)CCC4(C)C3CCC12C,Liver disorder,Rat,-0.7781512503836436,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Eksperimental'naya i Klinicheskaya Farmakologiya 57,35,1994   ---   ISSN:0869-2092   JOURNAL:Eksperimental'naya i Klinicheskaya Farmakologiya   PAGES:35   VOLUME:57",,1994.0
87,143,472,Clarithromycin,CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(OC)CC(C)C(=O)C(C)C(O)C1(C)O,Liver disorder,Rat,-1.224014811372864,Repeated,Oral,"FDA approval package document: Approval Package 050697 Part 03, page:49 PDF 8015k",https://www.pharmapendium.com/browse/fda/Clarithromycin/ce1428b691306ef7efbf7a9f966d76dd?reference=49,1993.0
88,153,536,Cocaine Hydrochloride,COC(=O)C1C(OC(=O)C2=CC=CC=C2)CC2CCC1N2C,Liver disorder,Mouse,-0.8016323462331665,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologist 60,43,2001   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:43   VOLUME:60",,2001.0
89,154,543,Colchicine,COC1=C(OC)C(OC)=C2C(=C1)CCC(NC(C)=O)C1=CC(=O)C(OC)=CC=C12,Liver disorder,Rat,-0.6766936096248666,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 204820/S-000 Part 01, page:42 PDF 3330k",https://www.pharmapendium.com/browse/fda/Colchicine/c9281d3761d79a2caa36a59bea48addc?reference=42,2013.0
90,155,548,Colistimethate Sodium,CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)O)C(=O)NC(C(=O)NC(CCNCS(=O)(=O)O)C(=O)NC1CCNC(=O)C(C(C)O)NC(=O)C(CCNCS(=O)(=O)O)NC(=O)C(CCNCS(=O)(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCNCS(=O)(=O)O)NC1=O)C(C)O,Liver disorder,Mouse,0.0,Repeated,Intraperitoneal,"EMA approval document: Assessment Report EMA/913717/2011; EMEA/H/C/001225, page:19 PDF 812k",https://www.pharmapendium.com/browse/ema/Colistimethate Sodium/4508c8c604e3d56c9dceedbba7fdbea1?reference=19,2011.0
91,156,550,Copanlisib Dihydrochloride,COC1=C(OCCCN2CCOCC2)C=CC2=C3NCCN3C(=NC(=O)C3=CN=C(N)N=C3)N=C12,Liver disorder,Rat,-0.4771212547196624,Repeated,Intravenous,"FDA approval package document: Approval Package 209936/S-000 Part 02, page:32 PDF 11850k",https://www.pharmapendium.com/browse/fda/Copanlisib Dihydrochloride/3a7a918dba0779ad831f58c4b35fbbbb?reference=32,2017.0
92,157,552,Cosyntropin,CSCCC(NC(=O)C(CO)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(N)CO)C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CNC=N1)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(CCCN=C(N)N)C(=O)NC(CC1=CNC2=C1C=CC=C2)C(=O)NCC(=O)NC(CCCCN)C(=O)N1CCCC1C(=O)NC(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCN=C(N)N)C(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC1=CC=C(O)C=C1)C(=O)N1CCCC1C(=O)O)C(C)C)C(C)C)C(C)C,Liver disorder,Rat,-7.079181246047625,Repeated,Intracerebral,"Reference from PharmaPendium Published Toxicity: Naunyn-Schmiedeberg's Archives of Pharmacology 369(Suppl 1),R176,2004   ---   ISSN:0028-1298   JOURNAL:Naunyn-Schmiedeberg's Archives of Pharmacology   PAGES:R176   VOLUME:369",,2004.0
93,159,558,Cromolyn Sodium,O=C(O)C1=CC(=O)C2=C(OCC(O)COC3=C4C(=O)C=C(C(=O)O)OC4=CC=C3)C=CC=C2O1,Liver disorder,Rat,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 019188 Part 05, page:40 PDF 4102k",https://www.pharmapendium.com/browse/fda/Cromolyn Sodium/31283d355dc86c450a0ec448d4ca088d?reference=40,1989.0
94,161,568,Cyclosporine,C/C=C/CC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,Liver disorder,Rat,-0.8260748027008264,Repeated,Intraperitoneal,"Reference from PharmaPendium Published Toxicity: Toxicology 201,239,2004   ---   DOI:10.1016/J.TOX.2004.04.013   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:239   VOLUME:201",http://dx.doi.org/10.1016/J.TOX.2004.04.013,2004.0
95,162,579,Cysteine Hydrochloride,NC(CS)C(=O)O,Liver disorder,Rat,0.0,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: 617488269   ---   DOI:10.1293/tox.2017-0002   ISSN:0914-9198   JOURNAL:Journal of Toxicologic Pathology   PAGES:217   VOLUME:30,http://dx.doi.org/10.1293/tox.2017-0002,2017.0
96,166,583,Dapiprazole Hydrochloride,CC1=CC=CC=C1N1CCN(CCC2=NN=C3CCCCN32)CC1,Liver disorder,Rat,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Approval Package 019849 Part 03, page:1 PDF 361k",https://www.pharmapendium.com/browse/fda/Dapiprazole Hydrochloride/fbc930975e874d877958f3bec17a7a40?reference=1,1990.0
97,167,584,Darifenacin Hydrobromide,NC(=O)C(C1=CC=CC=C1)(C1=CC=CC=C1)C1CCN(CCC2=CC3=C(C=C2)OCC3)C1,Liver disorder,Rat,-1.0,Repeated,Unreported,"EMA approval document: Scientific Discussion, page:11 PDF 463k",https://www.pharmapendium.com/browse/ema/Darifenacin Hydrobromide/5bf1f57942a4baf13fc1d4f966556ee6?reference=11,2005.0
98,169,586,Daunorubicin Citrate,COC1=C2C(O)=C3C(O)=C4C(OC5CC(N)C(O)C(C)O5)=CC(O)(C(C)=O)CC4=C(O)C3=C(O)C2=CC=C1,Liver disorder,Rat,-0.3010299956639812,Repeated,Intravenous,"FDA approval package document: Approval Package 050704 Part 02, page:76 PDF 7258k",https://www.pharmapendium.com/browse/fda/Daunorubicin Citrate/73ddd44a7d97e6350c5777e4e0679153?reference=76,1995.0
99,170,587,Deferiprone,CC1=C(O)C(=O)C=CN1C,Liver disorder,Rat,-1.8750612633917,Repeated,Oral,"FDA approval package document: Pharmacology Review 021825/S-000, page:57 PDF 889k",https://www.pharmapendium.com/browse/fda/Deferiprone/141f7384ecc42c2840561a32d535fc40?reference=57,2011.0
100,172,590,Deoxycholic Acid,CC(CCC(=O)O)C1CCC2C3CCC4CC(O)CCC4(C)C3CC(O)C12C,Liver disorder,Mouse,-0.3010299956639812,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 362682187   ---   DOI:10.1093/toxsci/kfr177   ISSN:1096-6080   JOURNAL:Toxicological Sciences   PAGES:359   VOLUME:123,http://dx.doi.org/10.1093/toxsci/kfr177,2011.0
101,173,592,Desonide,CC1(C)OC2CC3C4CC=C5CC(=O)C=CC5(C)C4C(O)CC3(C)C2(C(=O)CO)O1,Liver disorder,Rabbit,-0.6989700043360189,Repeated,Skin,"FDA approval package document: Approval Package 019048/S-001, S-002, S-003, S-004, S-005, S-006, S-007, S-009, S-010, S-011, S-012 Part 01, page:38 PDF 3610k",https://www.pharmapendium.com/browse/fda/Desonide/0abf5e9c6674dbbbe3aad76d6b584e0e?reference=38,1984.0
102,174,593,Deutetrabenazine,[2H]C([2H])([2H])OC1=C(OC([2H])([2H])[2H])C=C2C(=C1)CCN1CC(CC(C)C)C(=O)CC21,Liver disorder,Rat,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Pharmacology Review 208082/S-000, page:61 PDF 10655k",https://www.pharmapendium.com/browse/fda/Deutetrabenazine/1ab26b0cb18be4a2c25665aac20b5172?reference=61,2016.0
103,184,646,Didanosine,O=C1NC=NC2=C1N=CN2C1CCC(CO)O1,Liver disorder,Mouse,-0.6020599913279624,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 604820658   ---   DOI:10.1371/journal.pone.0085637   ISSN:1932-6203   JOURNAL:PLoS ONE   VOLUME:9,http://dx.doi.org/10.1371/journal.pone.0085637,2014.0
104,185,648,Diethylenetriaminepentaacetic Acid,O=C(O)CN(CCN(CC(=O)O)CC(=O)O)CCN(CC(=O)O)CC(=O)O,Liver disorder,Rat,-1.1760912590556811,Repeated,Intraperitoneal,"Reference from PharmaPendium Published Toxicity: food and chemical toxicology 39,1029,2001   ---   DOI:10.1016/S0278-6915(01)00046-1   ISSN:0278-6915   JOURNAL:Food and Chemical Toxicology   PAGES:1029   VOLUME:39",http://dx.doi.org/10.1016/S0278-6915(01)00046-1,2001.0
105,186,649,Diethylstilbestrol,CC=C(C1=CC=C(O)C=C1)C(CC)C1=CC=C(O)C=C1,Liver disorder,Mouse,-5.397945220174552,Repeated,Subcutaneous,"Reference from PharmaPendium Published Toxicity: toxicology and applied pharmacology 183,10,2002   ---   DOI:10.1006/TAAP.2002.9459   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:10   VOLUME:183",http://dx.doi.org/10.1006/TAAP.2002.9459,2002.0
106,187,655,Diltiazem Hydrochloride,COC1=CC=C(C2SC3=CC=CC=C3N(CCN(C)C)C(=O)C2OC(C)=O)C=C1,Liver disorder,Rat,-1.7160033436347992,Repeated,Oral,"FDA approval package document: Approval Package 020062/S-001, S-002, S-003, S-004, S-011, S-018 Part 06, page:25 PDF 6267k",https://www.pharmapendium.com/browse/fda/Diltiazem Hydrochloride/86ac93d8e0291da68ace50cdd7e3e617?reference=25,1994.0
107,188,657,Diltiazem Malate,COC1=CC=C(C2SC3=C(C=CC=C3)N(CCN(C)C)C(=O)C2OC(C)=O)C=C1,Liver disorder,Rat,-0.6020599913279624,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologist 12,476,2008   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:476   VOLUME:12",,2008.0
108,189,658,Dimethyl Fumarate,COC(=O)/C=C/C(=O)OC,Liver disorder,Rat,-2.1760912590556813,Repeated,Oral,"EMA approval document: Assessment Report EMA/800904/2013; EMEA/H/C/002601/0000/Rev 1, page:22 PDF 6911k",https://www.pharmapendium.com/browse/ema/Dimethyl Fumarate/f1e215f3f688394efb5a7de33e8e61e1?reference=22,2013.0
109,190,660,Dimethyl Sulfoxide,C[S+](C)[O-],Liver disorder,Rat,-6.477121254719663,Repeated,Intraperitoneal,"Reference from PharmaPendium Published Toxicity: British Journal of Pharmacology 139,787,2003   ---   DOI:10.1038/SJ.BJP.0705305   ISSN:0007-1188   JOURNAL:British Journal of Pharmacology   PAGES:787   VOLUME:139",http://dx.doi.org/10.1038/SJ.BJP.0705305,2003.0
110,191,661,Diphenhydramine Hydrochloride,CN(C)CCOC(C1=CC=CC=C1)C1=CC=CC=C1,Liver disorder,Rat,-2.0863598306747484,Repeated,Inhalation,"Reference from PharmaPendium Published Toxicity: Toksikologicheskii Vestnik (3),38,1995   ---   ISSN:0869-7922   JOURNAL:Toksikologicheskii Vestnik   PAGES:38",,1995.0
111,192,662,Doxazosin Mesylate,COC1=CC2=NC(N3CCN(C(=O)C4COC5=CC=CC=C5O4)CC3)=NC(N)=C2C=C1OC,Liver disorder,Mouse,-1.9420080530223127,Repeated,Oral,"FDA approval package document: Approval Package 019668/S-001, S-002, S-003, S-004, S-007 Part 16, page:38 PDF 5273k",https://www.pharmapendium.com/browse/fda/Doxazosin Mesylate/c89d5422b22dfbd9b8c49eee5638a6b8?reference=38,1990.0
112,193,664,Doxepin Hydrochloride,CN(C)CC/C=C1/C2=CC=CC=C2COC2=CC=CC=C12,Liver disorder,Rabbit,-2.2612628687924934,Repeated,Oral,"FDA approval package document: Pharmacology Review 022036/S-000 Part 02, page:25 PDF 3817k",https://www.pharmapendium.com/browse/fda/Doxepin Hydrochloride/e4a5d32bf2db1659353897d60410d118?reference=25,2009.0
113,194,668,Doxorubicin Hydrochloride,COC1=CC=CC2=C(O)C3=C(O)C4=CC(O)(C(=O)CO)CC(OC5CC(N)C(O)C(C)O5)=C4C(O)=C3C(O)=C12,Liver disorder,Mouse,-0.9667590668613208,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 51536304   ---   DOI:10.1111/j.1742-7843.2011.00748.x   ISSN:1742-7835   JOURNAL:Basic and Clinical Pharmacology and Toxicology   PAGES:452   VOLUME:109,http://dx.doi.org/10.1111/j.1742-7843.2011.00748.x,2011.0
114,195,688,Doxycycline,CC1C2=C(C(=O)C3C(=O)C4(O)C(=O)C(C(N)=O)C(=O)C(N(C)C)C4C(O)C31)C(O)=CC=C2,Liver disorder,Mouse,-1.146128035678238,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 602970642   ---   DOI:10.1016/j.celrep.2015.02.034   ISSN:2211-1247   JOURNAL:Cell Reports   PAGES:1681   VOLUME:10,http://dx.doi.org/10.1016/j.celrep.2015.02.034,2015.0
115,197,690,Dronabinol,CCCCCC1=CC2=C(C(O)=C1)C1C=C(C)CCC1C(C)(C)O2,Liver disorder,Rat,-2.439332693830263,Repeated,Oral,"FDA approval package document: Approval Package 018651/S-006 Part 01, page:38 PDF 5651k",https://www.pharmapendium.com/browse/fda/Dronabinol/a26db6ea029f417cea6a3decb7fbb338?reference=38,1985.0
116,198,692,Dronedarone Hydrochloride,CCCCC1=C(C(=O)C2=CC=C(OCCCN(CCCC)CCCC)C=C2)C2=CC(NS(C)(=O)=O)=CC=C2O1,Liver disorder,Mouse,-0.8450980400142568,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: E-373313038   ---   DOI:10.1016/j.tox.2014.05.011   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:1   VOLUME:323,http://dx.doi.org/10.1016/j.tox.2014.05.011,2014.0
117,199,693,Edaravone,CC1=CC(=O)N(C2=CC=CC=C2)N1,Liver disorder,Rat,-2.646730386247423,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 209176/S-000 Part 04, page:34 PDF 3193k",https://www.pharmapendium.com/browse/fda/Edaravone/2d7e01eeb9dd302b418b28cd3289158d?reference=34,2017.0
118,203,704,Eletriptan Hydrobromide,CN1CCCC1CC1=CNC2=C1C=C(CCS(=O)(=O)C1=CC=CC=C1)C=C2,Liver disorder,Mouse,-2.3640817414110704,Repeated,Oral,"FDA approval package document: Pharmacology Review 021016/S-000 Part 01, page:43 PDF 1977k",https://www.pharmapendium.com/browse/fda/Eletriptan Hydrobromide/f735f6506578d3a0425a66934cbf0624?reference=43,2002.0
119,204,708,Eliglustat Tartrate,CCCCCCCC(=O)NC(CN1CCCC1)C(O)C1=CC=C2OCCOC2=C1,Liver disorder,Mouse,-1.8588378514285853,Repeated,Oral,"FDA approval package document: Pharmacology Review 205494/S-000, page:131 PDF 42611k",https://www.pharmapendium.com/browse/fda/Eliglustat Tartrate/4c18e702d090574e7c17298d834dd84d?reference=131,2013.0
120,209,722,Enoxolone,CC1(C(=O)O)CCC2(C)CCC3(C)C(=C2C1)CC(=O)C1C2(C)CCC(O)C(C)(C)C2CCC13C,Liver disorder,Mouse,-1.1139433523068367,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Life Sciences 69,2429,2001   ---   DOI:10.1016/S0024-3205(01)01317-0   ISSN:0024-3205   JOURNAL:Life Sciences   PAGES:2429   VOLUME:69",http://dx.doi.org/10.1016/S0024-3205(01)01317-0,2001.0
121,210,724,Entacapone,CCN(CC)C(=O)C(C#N)=CC1=CC([N+](=O)[O-])=C(O)C(O)=C1,Liver disorder,Rat,-1.1903316981702914,Repeated,,"Reference from PharmaPendium Published Toxicity: Toxicologist -,334,2009   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:334",,2009.0
122,213,738,Epinephrine,CNCC(O)C1=CC=C(O)C(O)=C1,Liver disorder,Rat,-0.7781512503836436,Repeated,Subcutaneous,"Reference from PharmaPendium Published Toxicity: Toxicology and Applied Pharmacology 25,315,1973   ---   DOI:10.1016/0041-008X(73)90305-0   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:315   VOLUME:25",http://dx.doi.org/10.1016/0041-008X(73)90305-0,1973.0
123,214,739,Epirubicin Hydrochloride,COC1=C2C(O)=C3C(O)=C4C(OC5CC(N)C(O)C(C)O5)=CC(O)(C(=O)CO)CC4=C(O)C3=C(O)C2=CC=C1,Liver disorder,Mouse,-0.4771212547196624,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 2004212589   ---   DOI:10.1007/s10554-020-01777-w   ISSN:1569-5794   JOURNAL:International Journal of Cardiovascular Imaging   PAGES:841   VOLUME:36,http://dx.doi.org/10.1007/s10554-020-01777-w,2020.0
124,216,746,Ergonovine Maleate,CC(CO)NC(=O)C1=CC2C3=CC=CC4=C3C(=CN4)CC2N(C)C1,Liver disorder,Rat,-0.6020599913279624,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Food and Chemical Toxicology 34,951,1996   ---   DOI:10.1016/S0278-6915(96)00060-9   ISSN:0278-6915   JOURNAL:Food and Chemical Toxicology   PAGES:951   VOLUME:34",http://dx.doi.org/10.1016/S0278-6915(96)00060-9,1996.0
125,217,747,Eribulin Mesylate,C=C1CC2CCC34CC5OC6C(OC7CCC(CC(=O)CC8C(CC9OC(CCC1O2)CC(C)C9=C)OC(CC(O)CN)C8OC)OC7C6O3)C5O4,Liver disorder,Rat,-1.1760912590556811,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 201532/S-000 Part 05, page:3 PDF 310k",https://www.pharmapendium.com/browse/fda/Eribulin Mesylate/2d0d0f023398d17697aebe4f00a5abd1?reference=3,2010.0
126,218,748,Erythromycin,CCC1OC(=O)C(C)C(OC2CC(C)(OC)C(O)C(C)O2)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(O)CC(C)C(=O)C(C)C(O)C1(C)O,Liver disorder,Mouse,-1.724275869600789,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 52865876   ---   DOI:10.1111/fcp.12055   ISSN:0767-3981   JOURNAL:Fundamental and Clinical Pharmacology   PAGES:519   VOLUME:28,http://dx.doi.org/10.1111/fcp.12055,2014.0
127,219,750,Erythromycin Estolate,CCC(=O)OC1C(OC2C(C)C(OC3CC(C)(OC)C(O)C(C)O3)C(C)C(=O)OC(CC)C(C)(O)C(O)C(C)C(=O)C(C)CC2(C)O)OC(C)CC1N(C)C,Liver disorder,Rat,-0.9030899869919436,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: E-372247594   ---   DOI:10.1016/j.fct.2013.12.050   ISSN:0278-6915   JOURNAL:Food and Chemical Toxicology   PAGES:139   VOLUME:65,http://dx.doi.org/10.1016/j.fct.2013.12.050,2014.0
128,220,753,Eslicarbazepine Acetate,CC(=O)OC1CC2=C(C=CC=C2)N(C(N)=O)C2=C1C=CC=C2,Liver disorder,Mouse,-2.3891660843645326,Repeated,Oral,"FDA approval package document: Pharmacology Review 022416/S-000 Part 12, page:49 PDF 5225k",https://www.pharmapendium.com/browse/fda/Eslicarbazepine Acetate/69def65e90334065195d6525ec9135c2?reference=49,2009.0
129,222,764,Estradiol,CC12CCC3C4=C(C=C(O)C=C4)CCC3C1CCC2O,Liver disorder,Mouse,-1.6967930850817443,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologist 60,155,2001   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:155   VOLUME:60",,2001.0
131,224,773,Estradiol Valerate,CCCCC(=O)OC1CCC2C3CCC4=C(C=CC(O)=C4)C3CCC12C,Liver disorder,Rat,-6.397940877260133,Repeated,Subcutaneous,"Reference from PharmaPendium Published Toxicity: Phytomedicine 13,468,2006   ---   DOI:10.1016/j.phymed.2005.03.012   ISSN:0944-7113   JOURNAL:Phytomedicine   PAGES:468   VOLUME:13",http://dx.doi.org/10.1016/j.phymed.2005.03.012,2006.0
132,225,775,Ethambutol Hydrochloride,CCC(CO)NCCNC(CC)CO,Liver disorder,Rat,-1.7201593034059568,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: 603514884   ---   DOI:10.1055/s-0034-1382076   ISSN:2194-9379   JOURNAL:Drug Research   PAGES:219   VOLUME:65,http://dx.doi.org/10.1055/s-0034-1382076,2015.0
133,226,777,Ethanolamine Oleate,CCCCCCCC/C=C\CCCCCCCC(=O)O,Liver disorder,Rat,-1.4771212547196624,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Gigiena i Sanitariya 29(2),9,1964   ---   ISSN:0016-9900   JOURNAL:Gigiena i Sanitariya   PAGES:9   VOLUME:29",,1964.0
134,227,778,Ethinyl Estradiol,C#CC1(O)CCC2C3CCC4=C(C=CC(O)=C4)C3CCC21C,Liver disorder,Mouse,-7.558022520642876,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 53191033   ---   DOI:10.1002/tox.22013   ISSN:1520-4081   JOURNAL:Environmental Toxicology   PAGES:1434   VOLUME:30,http://dx.doi.org/10.1002/tox.22013,2015.0
135,228,786,Ethionamide,CCC1=NC=CC(C(N)=S)=C1,Liver disorder,Rat,-0.6020599913279624,Repeated,Oral,Reference from PharmaPendium Published Toxicity: E-373679540   ---   DOI:10.1016/j.tox.2014.07.005   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:43   VOLUME:324,http://dx.doi.org/10.1016/j.tox.2014.07.005,2014.0
136,229,787,Etomidate,CCOC(=O)C1=CN=CN1C(C)C1=CC=CC=C1,Liver disorder,Rat,-1.4913616938342726,Repeated,Intravenous,"FDA approval package document: Approval Package 018228 Part 02, page:47 PDF 5055k",https://www.pharmapendium.com/browse/fda/Etomidate/e24aa8f4a61fa838da9f6ede3185aac3?reference=47,1982.0
137,230,788,Etoposide,COC1=C(O)C(OC)=CC(C2C3=CC4=C(C=C3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)=C1,Liver disorder,Rat,-0.7269987279362623,Repeated,Intravenous,"Reference from PharmaPendium Published Toxicity: Toxicologist 44,364,2005   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:364   VOLUME:44",,2005.0
138,231,791,Etoposide Phosphate,COC1=C(O[PH](=O)(=O)O)C(OC)=CC(C2C3=CC4=C(C=C3C(OC3OC5COC(C)OC5C(O)C3O)C3COC(=O)C23)OCO4)=C1,Liver disorder,Rat,-0.3010299956639812,Repeated,Intravenous,"Reference from PharmaPendium Published Toxicity: Toxicologist 44,364,2005   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:364   VOLUME:44",,2005.0
139,232,792,Everolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(OCCO)C(OC)C2)CC(=O)C(C)=CC(C)C(O)C(OC)C(=O)C(C)CC(C)/C=C/C=C/C=C/1C,Liver disorder,Rat,-0.4771212547196624,Repeated,Oral,"FDA approval package document: Pharmacology Review 021560/S-000, page:92 PDF 1034k",https://www.pharmapendium.com/browse/fda/Everolimus/b064a5cc36268a2e253433507c1e4c37?reference=92,2009.0
140,235,799,Famotidine,N=C(CCSCC1=CSC(N=C(N)N)=N1)NS(N)(=O)=O,Liver disorder,Rabbit,-3.0211892990699383,Repeated,Oral,"FDA approval package document: Approval Package 019462/S-003 Part 03, page:13 PDF 2509k",https://www.pharmapendium.com/browse/fda/Famotidine/3e7debb6426723092a647471577502b1?reference=13,1986.0
141,239,821,Fenoprofen Calcium,CC(C(=O)O)C1=CC=CC(OC2=CC=CC=C2)=C1,Liver disorder,Rat,-2.544068044350276,Repeated,Oral,"FDA approval package document: Approval Package 017604 Part 02, page:58 PDF 4454k",https://www.pharmapendium.com/browse/fda/Fenoprofen Calcium/57d77bdfa2acbc92c786fdeb688faa85?reference=58,1971.0
142,240,822,Fentanyl,CCC(=O)N(C1=CC=CC=C1)C1CCN(CCC2=CC=CC=C2)CC1,Liver disorder,Mouse,-1.3222192947339193,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 2004894721   ---   DOI:10.1016/j.lfs.2020.117400   ISSN:0024-3205   JOURNAL:Life Sciences   PAGES:117400   VOLUME:246,http://dx.doi.org/10.1016/j.lfs.2020.117400,2020.0
143,243,825,Feprazone,CC(C)=CCC1=C(O)N(C2=CC=CC=C2)N(C2=CC=CC=C2)C1=O,Liver disorder,Rat,-2.0211892990699383,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicology and Applied Pharmacology 64,255,1982   ---   DOI:10.1016/0041-008X(82)90222-8   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:255   VOLUME:64",http://dx.doi.org/10.1016/0041-008X(82)90222-8,1982.0
144,244,828,Finasteride,CC(C)(C)NC(=O)C1CCC2C3CCC4NC(=O)C=CC4(C)C3CCC12C,Liver disorder,Mouse,-1.4771212547196624,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 627109479   ---   DOI:10.1177/0960327119842195   ISSN:0960-3271   JOURNAL:Human and Experimental Toxicology   PAGES:762   VOLUME:38,http://dx.doi.org/10.1177/0960327119842195,2019.0
145,245,831,Fingolimod Hydrochloride,CCCCCCCCC1=CC=C(CCC(N)(CO)CO)C=C1,Liver disorder,Rat,-0.8846065812979305,Repeated,Oral,"FDA approval package document: Pharmacology Review 022527/S-000 Part 06, page:173 PDF 6599k",https://www.pharmapendium.com/browse/fda/Fingolimod Hydrochloride/d9de1be3d0e4a1f28879ac70b76a8d13?reference=173,2009.0
146,258,870,Fomepizole,CC1=CNN=C1,Liver disorder,Rat,-1.6532125137753435,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologist -,237,2009   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:237",,2009.0
147,259,871,Formaldehyde,C=O,Liver disorder,Rat,-1.7423322823571483,Repeated,Inhalation,"Reference from PharmaPendium Published Toxicity: Vrednie chemichescie veshestva, galogen I kislorod sodergashie organicheskie soedinenia -,338,1994   ---   JOURNAL:Vrednie chemichescie veshestva. Galogen I kislorod sodergashie organicheskie soedinenia   PAGES:338",,1994.0
148,260,875,Fosfomycin Tromethamine,NC(CO)(CO)CO,Liver disorder,Rat,-3.505149978319906,Repeated,Oral,"FDA approval package document: Approval Package 050717 Part 02, page:14 PDF 6609k",https://www.pharmapendium.com/browse/fda/Fosfomycin Tromethamine/57716b212fda925b3c5c75eed28db01f?reference=14,1996.0
149,261,876,Frovatriptan Succinate,CNC1CCC2=C(C1)C1=C(C=CC(C(N)=O)=C1)N2,Liver disorder,Rat,-3.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 021006/S-000 Part 02, page:51 PDF 1571k",https://www.pharmapendium.com/browse/fda/Frovatriptan Succinate/351436d19cfebfaff3ca99171a737daa?reference=51,2001.0
150,262,880,Furazolidone,O=C1OCCN1/N=C/C1=CC=C([N+](=O)[O-])O1,Liver disorder,Rat,-0.4771212547196624,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Experimental and Toxicologic Pathology 52,364,2000   ---   DOI:10.1016/S0940-2993(00)80064-0   ISSN:0940-2993   JOURNAL:Experimental and Toxicologic Pathology   PAGES:364   VOLUME:52",http://dx.doi.org/10.1016/S0940-2993(00)80064-0,2000.0
151,264,883,Gabapentin,NCC1(CC(=O)O)CCCCC1,Liver disorder,Rat,-3.3452336581560345,Repeated,Oral,"FDA approval package document: Approval Package 020235 Part 05, page:73 PDF 7126k",https://www.pharmapendium.com/browse/fda/Gabapentin/cc544275f43b7ddbd40fd331f4f68e5a?reference=73,1993.0
152,265,890,Gabapentin Enacarbil,CC(OC(=O)NCC1(CC(=O)O)CCCCC1)OC(=O)C(C)C,Liver disorder,Rat,-3.397940008672037,Repeated,Oral,"FDA approval package document: Pharmacology Review 022399/S-000 Part 07, page:21 PDF 3886k",https://www.pharmapendium.com/browse/fda/Gabapentin Enacarbil/247e4b5eb8d6d2ea520cf7a9418dba4c?reference=21,2010.0
153,266,895,Gemfibrozil,CC1=CC(OCCCC(C)(C)C(=O)O)=C(C)C=C1,Liver disorder,Rat,-1.3617278360175928,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 361522984   ---   DOI:10.1016/S1734-1140(11)70410-8   ISSN:1734-1140   JOURNAL:Pharmacological Reports   PAGES:157   VOLUME:63,http://dx.doi.org/10.1016/S1734-1140(11)70410-8,2011.0
154,267,897,Gentamicin Sulfate,CNC(C)C1CCC(N)C(OC2C(N)CC(N)C(OC3OCC(C)(O)C(NC)C3O)C2O)O1,Liver disorder,Rat,-0.8750612633917001,Repeated,Subcutaneous,"Reference from PharmaPendium Published Toxicity: Toxicology 246,91,2008   ---   DOI:10.1016/j.tox.2007.12.031   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:91   VOLUME:246",http://dx.doi.org/10.1016/j.tox.2007.12.031,2008.0
155,268,899,Gilteritinib Fumarate,CCC1=NC(C(N)=O)=C(NC2=CC=C(N3CCC(N4CCN(C)CC4)CC3)C(OC)=C2)N=C1NC1CCOCC1,Liver disorder,Rat,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 211349/S-000 Part 04, page:9 PDF 1722k",https://www.pharmapendium.com/browse/fda/Gilteritinib Fumarate/aaf83e6ef6e98fadfda94387757b9708?reference=9,2018.0
156,269,900,Glasdegib,CN1CCC(NC(=O)NC2=CC=C(C#N)C=C2)CC1C1=NC2=C(C=CC=C2)N1,Liver disorder,Rat,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Pharmacology Review 210656/S-000 Part 08, page:13 PDF 3620k",https://www.pharmapendium.com/browse/fda/Glasdegib/327adbd54a4b96698cf06d05f8d68c1f?reference=13,2018.0
157,270,902,Glimepiride,CCC1=C(O)N(C(=O)NCCC2=CC=C(S(=O)(=O)NC(=O)NC3CCC(C)CC3)C=C2)C=C1C,Liver disorder,Rat,-1.1760912590556811,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: 603579990   ---   DOI:10.2174/1381612820666140318114832   ISSN:1381-6128   JOURNAL:Current Pharmaceutical Design   PAGES:5212   VOLUME:20,http://dx.doi.org/10.2174/1381612820666140318114832,2014.0
158,271,903,Glipizide,CC1=CN=C(C(=O)NCCC2=CC=C(S(=O)(=O)NC(=O)NC3CCCCC3)C=C2)C=N1,Liver disorder,Rat,-1.4771212547196624,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 364264441   ---   DOI:10.1166/jbn.2011.1317   ISSN:1550-7033   JOURNAL:Journal of Biomedical Nanotechnology   PAGES:578   VOLUME:7,http://dx.doi.org/10.1166/jbn.2011.1317,2011.0
159,272,904,Glucagon Recombinant,CSCCC(NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC(=O)O)NC(=O)C(CCC(N)=O)NC(=O)C(C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CCCCN)NC(=O)C(CO)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC1=CC=CC=C1)NC(=O)C(NC(=O)CNC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(N)CC1=CNC=N1)C(C)O)C(C)O)C(C)C)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)O)C(C)O,Liver disorder,Rat,-0.6989700043360189,Repeated,Intramuscular,"FDA approval package document: Pharmacology Review 201849/S-000, page:18 PDF 13257k",https://www.pharmapendium.com/browse/fda/Glucagon Recombinant/a1223ba9418faaefa71e642f75acbe58?reference=18,2010.0
160,274,907,Glycerol Phenylbutyrate,O=C(CCCC1=CC=CC=C1)OCC(COC(=O)CCCC1=CC=CC=C1)OC(=O)CCCC1=CC=CC=C1,Liver disorder,Rat,-4.678778435623874,Repeated,Oral,"FDA approval package document: Pharmacology Review 203284/S-000 Part 09, page:11 PDF 3369k",https://www.pharmapendium.com/browse/fda/Glycerol Phenylbutyrate/49fa5483c7e79c349351b4d2b7e6b28d?reference=11,2012.0
161,275,914,Glycine,NCC(=O)O,Liver disorder,Rat,-3.6020599913279625,Repeated,Intramuscular,"Reference from PharmaPendium Published Toxicity: Journal of Pharmacology and Experimental Therapeutics 299,858,2001   ---   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:858   VOLUME:299",,2001.0
162,276,915,Glycopyrrolate,C[N+]1(C)CCC(OC(=O)C(O)(C2=CC=CC=C2)C2CCCC2)C1,Liver disorder,Mouse,-2.0310042813635367,Repeated,Oral,"FDA approval package document: Pharmacology Review 207923/S-000 Part 05, page:10 PDF 316k",https://www.pharmapendium.com/browse/fda/Glycopyrrolate/01315a4318f5c40d04cce7c3267141dc?reference=10,2015.0
163,282,926,Histrelin Acetate,CCNC(=O)C1CCCN1C(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CC1=CN(CC2=CC=CC=C2)C=N1)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=C1C=CC=C2)NC(=O)C(CC1=CNC=N1)NC(O)C1=CC=C(O)N1,Liver disorder,Rat,-7.797036594544017,Repeated,Parenteral,"FDA approval package document: Approval Package 019836 Part 02, page:17 PDF 2429k",https://www.pharmapendium.com/browse/fda/Histrelin Acetate/98684a4d30b53a5512e81aec6b63f16d?reference=17,1991.0
164,283,929,Hycanthone,CCN(CC)CCNC1=C2C(=O)C3=C(C=CC=C3)SC2=C(CO)C=C1,Liver disorder,Mouse,-0.6989700043360189,Repeated,Intraperitoneal,"Reference from PharmaPendium Published Toxicity: Toxicologist 44,114,2005   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:114   VOLUME:44",,2005.0
165,284,930,Hydralazine Hydrochloride,NNC1=NN=CC2=CC=CC=C12,Liver disorder,Mouse,-0.8450980400142568,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 368814331   ---   DOI:10.1093/toxsci/kft066   ISSN:1096-6080   JOURNAL:Toxicological Sciences   PAGES:22   VOLUME:133,http://dx.doi.org/10.1093/toxsci/kft066,2013.0
166,286,933,Hydrocodone Bitartrate,COC1=C2OC3C(=O)CCC4C5CC(=C2C34CCN5C)C=C1,Liver disorder,Rat,-1.4648867983026508,Repeated,Oral,"FDA approval package document: Pharmacology Review 202880/S-000, page:100 PDF 10609k",https://www.pharmapendium.com/browse/fda/Hydrocodone Bitartrate/5a63a46d07f6431881364e2c819aa68f?reference=100,2012.0
167,287,940,Hydrocortisone Sodium Succinate,CC12CCC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)COC(=O)CCC(=O)O,Liver disorder,Mouse,-0.8450980400142568,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 605675936   ---   DOI:10.1016/S2222-1808(15)60921-5   ISSN:2222-1808   JOURNAL:Asian Pacific Journal of Tropical Disease   PAGES:726   VOLUME:5,http://dx.doi.org/10.1016/S2222-1808(15)60921-5,2015.0
168,288,941,Hydromorphone Hydrochloride,CN1CCC23C4=C5C=CC(O)=C4OC2C(=O)CCC3C1C5,Liver disorder,Mouse,-0.6989700043360189,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 2008419974   ---   DOI:10.1093/ecco-jcc/jjz188   ISSN:1873-9946   JOURNAL:Journal of Crohn's and Colitis   PAGES:801   VOLUME:14,http://dx.doi.org/10.1093/ecco-jcc/jjz188,2020.0
169,289,942,Hydroquinone,OC1=CC=C(O)C=C1,Liver disorder,Rat,-1.7596678446896306,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Food and Chemical Toxicology 30,737,1992   ---   DOI:10.1016/0278-6915(92)90075-V   ISSN:0278-6915   JOURNAL:Food and Chemical Toxicology   PAGES:737   VOLUME:30",http://dx.doi.org/10.1016/0278-6915(92)90075-V,1992.0
170,291,945,Ibandronate Sodium,CCCCCN(C)CCC(O)([PH](=O)(=O)O)[PH](=O)(=O)O,Liver disorder,Rat,-1.5314789170422551,Repeated,Oral,"FDA approval package document: Pharmacology Review 021455/S-000 Part 04, page:12 PDF 1311k",https://www.pharmapendium.com/browse/fda/Ibandronate Sodium/7044eb655968d1eb8b2fe63c5db46606?reference=12,2003.0
171,292,948,Ibrutinib,C=CC(=O)N1CCCC(N2N=C(C3=CC=C(OC4=CC=CC=C4)C=C3)C3=C(N)N=CN=C32)C1,Liver disorder,Rat,-2.355387657986574,Repeated,Oral,"EMA approval document: Assessment Report EMA/373867/2016; EMEA/H/C/003791/II/0016, page:12 PDF 4989k",https://www.pharmapendium.com/browse/ema/Ibrutinib/1ae8299578a99071602d1f71990059f4?reference=12,2016.0
172,293,951,Ibuprofen,CC(C)CC1=CC=C(C(C)C(=O)O)C=C1,Liver disorder,Mouse,-1.662757831681574,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 606297651   ---   DOI:10.1177/019262339302100102   ISSN:0192-6233   JOURNAL:Toxicologic Pathology   PAGES:15   VOLUME:21,http://dx.doi.org/10.1177/019262339302100102,1993.0
173,294,955,Icatibant Acetate,N=C(N)NCCCC(N)C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)N1CC(O)CC1C(=O)NCC(=O)NC(CC1=CC=CS1)C(=O)NC(CO)C(=O)N1CC2=CC=CC=C2CC1C(=O)N1C(C(=O)NC(CCCN=C(N)N)C(=O)O)CC2CCCCC21,Liver disorder,Mouse,-1.1317935832540489,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 022150/S-000 Part 05, page:16 PDF 897k",https://www.pharmapendium.com/browse/fda/Icatibant Acetate/df2dc8c42afba05284d96287d75f8ce5?reference=16,2007.0
174,295,966,Icosapent Ethyl,CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OCC,Liver disorder,Mouse,-2.812913356642856,Repeated,Oral,"FDA approval package document: Pharmacology Review 202057/S-000 Part 02, page:29 PDF 4715k",https://www.pharmapendium.com/browse/fda/Icosapent Ethyl/871607c88ef2c24ae8ca008e6956ebad?reference=29,2011.0
175,297,969,Imatinib Mesylate,CC1=C(NC2=NC(C3=CN=CC=C3)=CC=N2)C=C(NC(=O)C2=CC=C(CN3CCN(C)CC3)C=C2)C=C1,Liver disorder,Rat,-0.4259687322722812,Repeated,Oral,"FDA approval package document: Pharmacology Review 021335/S-000 Part 02, page:8 PDF 1215k",https://www.pharmapendium.com/browse/fda/Imatinib Mesylate/90aeb134ad6cbe3c7c727af34a25fbfe?reference=8,2001.0
176,298,972,Imipramine Hydrochloride,CN(C)CCCN1C2=CC=CC=C2CCC2=CC=CC=C21,Liver disorder,Rat,-0.8450980400142568,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 51930956   ---   DOI:10.1016/j.tox.2012.02.015   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:1   VOLUME:295,http://dx.doi.org/10.1016/j.tox.2012.02.015,2012.0
177,299,973,Inamrinone Lactate,NC1=CC(C2=CC=NC=C2)=CNC1=O,Liver disorder,Rat,-1.6532125137753435,Repeated,Oral,"FDA approval package document: Approval Package 018700/S-018, S-009, S-014 Part 02, page:29 PDF 9058k",https://www.pharmapendium.com/browse/fda/Inamrinone Lactate/0f967f44d41baf8b658c5d2772d3ba6c?reference=29,1984.0
178,300,975,Indacaterol Maleate,CCC1=CC2=C(C=C1CC)CC(NCC(O)C1=C3C=CC(=O)NC3=C(O)C=C1)C2,Liver disorder,Rat,-2.008600171761917,Repeated,Inhalation,"FDA approval package document: Pharmacology Review 022383/S-000 Part 04, page:18 PDF 2090k",https://www.pharmapendium.com/browse/fda/Indacaterol Maleate/ad92ac712ed040fd7b90de73359cee99?reference=18,2009.0
179,301,976,Indecainide Hydrochloride,CC(C)NCCCC1(C(N)=O)C2=C(C=CC=C2)C2=C1C=CC=C2,Liver disorder,Rat,-0.4771212547196624,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Fundamental and Applied Toxicology 5,175,1985   ---   DOI:10.1016/0272-0590(85)90127-7   ISSN:0272-0590   JOURNAL:Fundamental and Applied Toxicology   PAGES:175   VOLUME:5",http://dx.doi.org/10.1016/0272-0590(85)90127-7,1985.0
180,302,977,Indinavir Sulfate,CC(C)(C)NC(=O)C1CN(CC2=CC=CN=C2)CCN1CC(O)CC(CC1=CC=CC=C1)C(=O)NC1C2=CC=CC=C2CC1O,Liver disorder,Mouse,-2.7592480336546177,Repeated,Oral,"FDA approval package document: Pharmacology Review 020685, page:31 PDF 2098k",https://www.pharmapendium.com/browse/fda/Indinavir Sulfate/d214ba9ff666ee648ab3c78ad1eff978?reference=31,1996.0
181,304,991,Insulin Aspart,CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(CC3=CNC=N3)NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC3=CC=CC=C3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC3=CNC=N3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(CC3=CC=C(O)C=C3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)NC(CC3=CC=CC=C3)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CC3=CC=C(O)C=C3)C(=O)NC(C(=O)NC(CC(=O)O)C(=O)NC(CCCCN)C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(CC3=CC=C(O)C=C3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(CC3=CC=C(O)C=C3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C,Liver disorder,Rat,-8.096910013008056,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 020986/S-000 Part 02, page:39 PDF 1444k",https://www.pharmapendium.com/browse/fda/Insulin Aspart/a46cf96b50abb270e29554194bd37c59?reference=39,2000.0
182,305,993,Insulin Glulisine,CCC(C)C(NC(=O)CN)C(=O)NC(C(=O)NC(CCC(=O)O)C(=O)NC(CCC(N)=O)C(=O)NC1CSSCC2NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CSSCC(NC(=O)C(CC(C)C)NC(=O)C(CC3=CNC=N3)NC(=O)C(CCC(N)=O)NC(=O)C(CCCCN)NC(=O)C(NC(=O)C(N)CC3=CC=CC=C3)C(C)C)C(=O)NCC(=O)NC(CO)C(=O)NC(CC3=CNC=N3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(C)C(=O)NC(CC(C)C)C(=O)NC(CC3=CC=C(O)C=C3)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(C(=O)NCC(=O)NC(CCC(=O)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)NC(CC3=CC=CC=C3)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CC3=CC=C(O)C=C3)C(=O)NC(C(=O)N3CCCC3C(=O)NC(CCC(=O)O)C(=O)NC(C(=O)O)C(C)O)C(C)O)CSSCC(C(=O)NC(CC(N)=O)C(=O)O)NC(=O)C(CC3=CC=C(O)C=C3)NC(=O)C(CC(N)=O)NC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CCC(N)=O)NC(=O)C(CC3=CC=C(O)C=C3)NC(=O)C(CC(C)C)NC(=O)C(CO)NC2=O)NC1=O)C(C)C,Liver disorder,Rat,-7.375663613960885,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 021629/S-000 Part 02, page:3 PDF 861k",https://www.pharmapendium.com/browse/fda/Insulin Glulisine/9e84c0e5debf064212e22cbca807bf30?reference=3,2004.0
183,306,997,Iodoform,IC(I)I,Liver disorder,Rat,-1.5440680443502757,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Gigiena i Sanitariya 52(11),74,1987   ---   ISSN:0016-9900   JOURNAL:Gigiena i Sanitariya   PAGES:74   VOLUME:52",,1987.0
184,307,998,Iofetamine Hydrochloride I-123,CC(C)NC(C)CC1=CC=C([123I])C=C1,Liver disorder,Rat,-0.7781512503836436,Repeated,Intravenous,"FDA approval package document: Approval Package 019432/S-001, page:34 PDF 4383k",https://www.pharmapendium.com/browse/fda/Iofetamine Hydrochloride I-123/b3e381d1ca86ccc7766c35da69055c8c?reference=34,1987.0
185,308,999,Ipratropium Bromide,CC(C)[N+]1(C)C2CCC1CC(OC(=O)C(CO)C1=CC=CC=C1)C2,Liver disorder,Rat,-8.41306120790347,Repeated,Oral,"FDA approval package document: Pharmacology Review 020394, page:13 PDF 1033k",https://www.pharmapendium.com/browse/fda/Ipratropium Bromide/4cc345ed604f3560ae3ca4a005ec5989?reference=13,1992.0
186,309,1006,Irbesartan,CCCCC1=NC2(CCCC2)C(=O)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,Liver disorder,Mouse,-3.1297972712286284,Repeated,Oral,"FDA approval package document: Pharmacology Review 020758 Part 03, page:8 PDF 2614k",https://www.pharmapendium.com/browse/fda/Irbesartan/28e2043b06ba9b75e4f0c9e8934272e3?reference=8,1997.0
187,310,1012,Irinotecan Hydrochloride,CCC1=C2CN3C(=CC4=C(COC(=O)C4(O)CC)C3=O)C2=NC2=CC=C(OC(=O)N3CCC(N4CCCCC4)CC3)C=C12,Liver disorder,Mouse,-0.7403626894942439,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 607336473   ---   DOI:10.1016/j.taap.2015.12.003   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:21   VOLUME:291,http://dx.doi.org/10.1016/j.taap.2015.12.003,2016.0
188,313,1020,Isoniazid,NNC(=O)C1=CC=NC=C1,Liver disorder,Rat,-1.859338479128867,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 51595582   ---   DOI:10.1016/j.etap.2011.07.001   ISSN:1382-6689   JOURNAL:Environmental Toxicology and Pharmacology   PAGES:486   VOLUME:32,http://dx.doi.org/10.1016/j.etap.2011.07.001,2011.0
189,314,1023,Isoproterenol Hydrochloride,CC(C)NCC(O)C1=CC=C(O)C(O)=C1,Liver disorder,Rat,-0.6020599913279624,Repeated,Subcutaneous,"Reference from PharmaPendium Published Toxicity: Toxicologist 72,177,2003   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:177   VOLUME:72",,2003.0
190,315,1024,Istradefylline,CCN1C(=O)C2=C(N=C(/C=C/C3=CC=C(OC)C(OC)=C3)N2C)N(CC)C1=O,Liver disorder,Rabbit,-2.060697840353612,Repeated,Oral,"FDA approval package document: Pharmacology Review 022075/S-000 Part 07, page:9 PDF 1466k",https://www.pharmapendium.com/browse/fda/Istradefylline/54f7f461b345a77a73fc5f9d718a7d9f?reference=9,2008.0
191,317,1031,Ivacaftor,CC(C)(C)C1=C(O)C=C(NC(=O)C2=CNC3=CC=CC=C3C2=O)C(C(C)(C)C)=C1,Liver disorder,Rat,-2.096910013008056,Repeated,Oral,"FDA approval package document: Pharmacology Review 203188/S-000 Part 03, page:3 PDF 291k",https://www.pharmapendium.com/browse/fda/Ivacaftor/afd67793d31b528524b251d348f90bfd?reference=3,2012.0
192,319,1037,Ixabepilone,C/C(=C\C1=CSC(C)=N1)C1CC2OC2(C)CCCC(C)C(O)C(C)C(=O)C(C)(C)C(O)CC(=O)N1,Liver disorder,Rabbit,-0.4771212547196624,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 022065/S-000 Part 02, page:88 PDF 6823k",https://www.pharmapendium.com/browse/fda/Ixabepilone/faa52222d993926e525f8a65e0014d74?reference=88,2007.0
193,322,1047,Ketorolac Tromethamine,O=C(C1=CC=CC=C1)C1=CC=C2C(C(=O)O)CCN12,Liver disorder,Rat,-0.3010299956639812,Repeated,Intranasal,"FDA approval package document: Pharmacology Review 022382/S-000 Part 02, page:4 PDF 956k",https://www.pharmapendium.com/browse/fda/Ketorolac Tromethamine/11490508a1c8290b0e52d83976bcca17?reference=4,2008.0
194,323,1049,Ketotifen Fumarate,CN1CCC(=C2C3=CC=CC=C3CC(=O)C3=C2C=CS3)CC1,Liver disorder,Rat,-1.5522625229655471,Repeated,Oral,"FDA approval package document: Pharmacology Review 021066 Part 02, page:44 PDF 1870k",https://www.pharmapendium.com/browse/fda/Ketotifen Fumarate/c588463a72ae5155995cfc0148b9eae7?reference=44,1999.0
195,324,1056,Lacosamide,COCC(NC(C)=O)C(=O)NCC1=CC=CC=C1,Liver disorder,Rat,-2.204119982655925,Repeated,Oral,"FDA approval package document: Pharmacology Review 022253/S-000; 022254/S-000 Part 03, page:44 PDF 5737k",https://www.pharmapendium.com/browse/fda/Lacosamide/4e8b8970d00652b38ee86ad5a3c78d75?reference=44,2008.0
196,330,1083,Lenalidomide,NC1=CC=CC2=C1CN(C1CCC(=O)NC1=O)C2=O,Liver disorder,Rat,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Pharmacology Review 021880/S-000, page:167 PDF 7676k",https://www.pharmapendium.com/browse/fda/Lenalidomide/979ec21cc5a29982bf5b65689b66eff2?reference=167,2005.0
197,334,1091,Letrozole,N#CC1=CC=C(C(C2=CC=C(C#N)C=C2)N2C=NC=N2)C=C1,Liver disorder,Rat,-1.6127838567197357,Repeated,Intravenous,"FDA approval package document: Medical/Clinical Review 020726/S-000 Part 01, page:27 PDF 1068k",https://www.pharmapendium.com/browse/fda/Letrozole/17f57ae7fd03fd8a979c63131cdb6d7a?reference=27,1997.0
198,335,1094,Leuprolide Acetate,CCNC(=O)C1CCCN1C(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CC1=CNC2=C1C=CC=C2)NC(=O)C(CC1=CNC=N1)NC(O)C1=CC=C(O)N1,Liver disorder,Rat,-0.7781512503836436,Repeated,Subcutaneous,"FDA approval package document: Approval Package 019010/S-004, S-002, S-003, S-005, S-006, S-008, S-009 Part 03, page:6 PDF 2943k",https://www.pharmapendium.com/browse/fda/Leuprolide Acetate/4b0519d08ab3e03eacd8f38334c7b340?reference=6,1985.0
199,336,1095,Levalbuterol Hydrochloride,CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1,Liver disorder,Rat,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Pharmacology Review 020837, page:29 PDF 2400k",https://www.pharmapendium.com/browse/fda/Levalbuterol Hydrochloride/60d714a0a129905c4a281032459d7191?reference=29,1998.0
200,337,1098,Levetiracetam,CCC(C(N)=O)N1CCCC1=O,Liver disorder,Rat,-2.9860823778010257,Repeated,Oral,"FDA approval package document: Pharmacology Review 021035, page:19 PDF 1699k",https://www.pharmapendium.com/browse/fda/Levetiracetam/fe534fda88fabd4471d10e41769e737b?reference=19,1999.0
201,339,1113,Levocarnitine,C[N+](C)(C)CC(O)CC(=O)[O-],Liver disorder,Mouse,-3.434196187604368,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: E-52661887   ---   DOI:10.1016/j.pbb.2013.06.002   ISSN:0091-3057   JOURNAL:Pharmacology Biochemistry and Behavior   PAGES:40   VOLUME:110,http://dx.doi.org/10.1016/j.pbb.2013.06.002,2013.0
202,342,1125,Levomilnacipran Hydrochloride,CCN(CC)C(=O)C1(C2=CC=CC=C2)CC1CN,Liver disorder,Rat,-2.026328938722349,Repeated,Oral,"FDA approval package document: Pharmacology Review 204168/S-000 Part 02, page:29 PDF 16517k",https://www.pharmapendium.com/browse/fda/Levomilnacipran Hydrochloride/af3376891ab8ae9c5f743692525cd591?reference=29,2012.0
203,343,1129,Levonorgestrel,C#CC1(O)CCC2C3CC=C4CC(=O)CCC4C3CCC21CC,Liver disorder,Rat,-1.3979400086720375,Repeated,Oral,"FDA approval package document: Pharmacology Review 206229/S-000 Part 02, page:6 PDF 304k",https://www.pharmapendium.com/browse/fda/Levonorgestrel/5f01bfeffc041ed064a64f2e688903cc?reference=6,2014.0
204,344,1130,Levothyroxine Sodium,NC(CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C(=O)O,Liver disorder,Rat,-8.406114195235645,Repeated,Subcutaneous,"Reference from PharmaPendium Published Toxicity: Toxicology and Applied Pharmacology 25,315,1973   ---   DOI:10.1016/0041-008X(73)90305-0   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:315   VOLUME:25",http://dx.doi.org/10.1016/0041-008X(73)90305-0,1973.0
205,345,1134,Linaclotide,CC1NC(=O)C2CCCN2C(=O)C(CC(N)=O)NC(=O)C2CSSCC(N)C(=O)NC3CSSCC(NC1=O)C(=O)NC(C(C)O)C(=O)NCC(=O)NC(C(=O)NC(CC1=CC=C(O)C=C1)C(=O)O)CSSCC(NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CCC(=O)O)NC3=O)C(=O)N2,Liver disorder,Rat,-2.028028723600244,Repeated,Oral,"FDA approval package document: Pharmacology Review 202811/S-000 Part 05, page:5 PDF 5808k",https://www.pharmapendium.com/browse/fda/Linaclotide/af932cbaaa7044bba6c0c9e8b8dfea31?reference=5,2012.0
206,346,1137,Linagliptin,CC#CCN1C(N2CCCC(N)C2)=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C,Liver disorder,Rat,-2.544068044350276,Repeated,Oral,"FDA approval package document: Pharmacology Review 201280/S-000 Part 02, page:34 PDF 2478k",https://www.pharmapendium.com/browse/fda/Linagliptin/263b32f319898c72d0e54678421a91eb?reference=34,2010.0
207,349,1141,Liraglutide,CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=C(O)C=C1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC1=CC=CC=C1)NC(=O)C(NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(N)CC1=CNC=N1)C(C)O)C(C)O)C(C)C)C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(=O)NC(C)C(=O)NC(CC1=CNC2=C1C=CC=C2)C(=O)NC(CC(C)C)C(=O)NC(C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)C(C)C)C(C)CC)C(=O)O,Liver disorder,Mouse,-0.3357921019231932,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 022341/S-000 Part 04, page:31 PDF 9545k",https://www.pharmapendium.com/browse/fda/Liraglutide/29f7df62d10eed1fb37d153f9489f857?reference=31,2010.0
208,350,1147,Lisinopril,NCCCCC(NC(CCC1=CC=CC=C1)C(=O)O)C(=O)N1CCCC1C(=O)O,Liver disorder,Rat,-0.7781512503836436,Repeated,Intraperitoneal,"Reference from PharmaPendium Published Toxicity: Brazilian Journal of Medical and Biological Research 34,125,2001   ---   DOI:10.1590/S0100-879X2001000100016   ISSN:0100-879X   JOURNAL:Brazilian Journal of Medical and Biological Research   PAGES:125   VOLUME:34",http://dx.doi.org/10.1590/S0100-879X2001000100016,2001.0
210,360,1194,Lovastatin,CCC(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,Liver disorder,Rat,-2.3324384599156054,Repeated,Oral,"FDA approval package document: Approval Package 019643/S-008, S-012, S-028, S-032, S-033, S-035, S-036, S-037, S-041, S-034, S-009, S-018, S-039, S-040, S-042 Part 04, page:12 PDF 4084k",https://www.pharmapendium.com/browse/fda/Lovastatin/09dd0161d126adc67153e88ec67ecacb?reference=12,1990.0
211,363,1199,Lurasidone Hydrochloride,OC1=C2C(=C(O)N1CC1CCCCC1CN1CCN(C3=NSC4=C3C=CC=C4)CC1)C1CCC2C1,Liver disorder,Rat,-2.4771212547196626,Repeated,Oral,"EMA approval document: Assessment Report EMA/113836/2014; EMEA/H/C/002713/0000, page:19 PDF 2824k",https://www.pharmapendium.com/browse/ema/Lurasidone Hydrochloride/194c2612915ca09c6100d9ae9bfa6934?reference=19,2014.0
213,366,1204,Malathion,CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC,Liver disorder,Rat,-1.3926969532596658,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 605888753   ---   DOI:10.1177/0748233713475507   ISSN:0748-2337   JOURNAL:Toxicology and Industrial Health   PAGES:783   VOLUME:31,http://dx.doi.org/10.1177/0748233713475507,2015.0
214,367,1219,Mannitol,OCC(O)C(O)C(O)C(O)CO,Liver disorder,Mouse,-0.0,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologic Pathology 32,192,2004   ---   DOI:10.1080/01926230490274344   ISSN:0192-6233   JOURNAL:Toxicologic Pathology   PAGES:192   VOLUME:32",http://dx.doi.org/10.1080/01926230490274344,2004.0
215,368,1220,Maprotiline Hydrochloride,CNCCCC12CCC(C3=C1C=CC=C3)C1=C2C=CC=C1,Liver disorder,Rat,-1.505149978319906,Repeated,Oral,"FDA approval package document: Approval Package 017543 Part 02, page:7 PDF 1949k",https://www.pharmapendium.com/browse/fda/Maprotiline Hydrochloride/82688c1ac32518ab514f4c0935204e83?reference=7,1960.0
216,370,1223,Mebendazole,COC(=O)NC1=NC2=C(C=CC(C(=O)C3=CC=CC=C3)=C2)N1,Liver disorder,Rat,-2.0453229787866576,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicology and Applied Pharmacology 24,371,1973   ---   DOI:10.1016/0041-008X(73)90043-4   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:371   VOLUME:24",http://dx.doi.org/10.1016/0041-008X(73)90043-4,1973.0
217,372,1227,Mefenamic Acid,CC1=C(C)C(NC2=CC=CC=C2C(=O)O)=CC=C1,Liver disorder,Mouse,-1.4771212547196624,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 2003470584   ---   DOI:10.2174/1389200220666191115103310   ISSN:1389-2002   JOURNAL:Current Drug Metabolism   PAGES:918   VOLUME:20,http://dx.doi.org/10.2174/1389200220666191115103310,2019.0
218,374,1229,Megestrol Acetate,CC(=O)OC1(C(C)=O)CCC2C3=CC(C)=C4CC(=O)CCC4(C)C3CCC21C,Liver disorder,Rat,-1.0,Repeated,Oral,"FDA approval package document: Approval Package 020264/S-000, page:52 PDF 5214k",https://www.pharmapendium.com/browse/fda/Megestrol Acetate/6ee6c06847a5f3c872a7cc10ed035fe4?reference=52,1993.0
219,375,1232,Melatonin,COC1=CC2=C(C=C1)NC=C2CCNC(C)=O,Liver disorder,Rat,-1.6967930850817443,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/556280/2018; EMEA/H/C/004425/0000, page:26 PDF 1326k",https://www.pharmapendium.com/browse/ema/Melatonin/181b5b4d07cbd8b8ba565c5d0b811186?reference=26,2018.0
220,376,1236,Meloxicam,CC1=CN=C(NC(=O)C2C(=O)C3=CC=CC=C3S(=O)(=O)N2C)S1,Liver disorder,Rat,-0.3424226808222063,Repeated,Oral,"FDA approval package document: Pharmacology Review 020938/S-000 Part 02, page:4 PDF 1466k",https://www.pharmapendium.com/browse/fda/Meloxicam/27970a1f0a2595854551980a6f7bf549?reference=4,1999.0
221,377,1242,Memantine Hydrochloride,CC12CC3CC(C)(C1)CC(N)(C3)C2,Liver disorder,Rat,-1.9382694834629115,Repeated,Oral,"FDA approval package document: Pharmacology Review 021487/S-000 Part 05, page:3 PDF 1822k",https://www.pharmapendium.com/browse/fda/Memantine Hydrochloride/46d984a4197aa52894750f8adda4767d?reference=3,2003.0
222,378,1261,Mephenoxalone,COC1=CC=CC=C1OCC1CNC(=O)O1,Liver disorder,Rat,-1.3222192947339193,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: toxicology and applied pharmacology 6,642,1964   ---   DOI:10.1016/0041-008X(64)90114-0   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:642   VOLUME:6",http://dx.doi.org/10.1016/0041-008X(64)90114-0,1964.0
223,379,1262,Metformin Hydrochloride,CN(C)C(N)=NC(=N)N,Liver disorder,Mouse,-1.0569048513364727,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 625755618   ---   DOI:10.7150/thno.30080   ISSN:1838-7640   JOURNAL:Theranostics   PAGES:77   VOLUME:9,http://dx.doi.org/10.7150/thno.30080,2019.0
224,380,1268,Methamphetamine Hydrochloride,CNC(C)CC1=CC=CC=C1,Liver disorder,Rat,-1.3679767852945943,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 2002558413   ---   DOI:10.1016/j.toxac.2019.07.007   ISSN:2352-0078   JOURNAL:Toxicologie Analytique et Clinique   PAGES:4   VOLUME:32,http://dx.doi.org/10.1016/j.toxac.2019.07.007,2020.0
225,381,1271,Methapyrilene Hydrochloride,CN(C)CCN(CC1=CC=CS1)C1=NC=CC=C1,Liver disorder,Rat,-0.8129133566428556,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicology 178,45,2002   ---   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:45   VOLUME:178",,2002.0
226,382,1275,Methionine,CSCCC(N)C(=O)O,Liver disorder,Mouse,-1.392110465011314,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologist 78,340,2004   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:340   VOLUME:78",,2004.0
227,383,1278,Methotrexate,CN(CC1=NC2=C(N)N=C(N)N=C2N=C1)C1=CC=C(C(=O)NC(CCC(=O)O)C(=O)O)C=C1,Liver disorder,Rat,-1.423245873936808,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 620365227   ---   DOI:10.1080/21691401.2018.1428811   ISSN:2169-1401   JOURNAL:Notiziario Chimico Farmaceutico   PAGES:402   VOLUME:46,http://dx.doi.org/10.1080/21691401.2018.1428811,2018.0
229,385,1284,Methoxsalen,COC1=C2OC(=O)C=CC2=CC2=C1OC=C2,Liver disorder,Rat,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Pharmacology Review 020969/S-000 Part 02, page:4 PDF 646k",https://www.pharmapendium.com/browse/fda/Methoxsalen/4cb71cf76dad97b7a0ad6c29e4045a34?reference=4,1999.0
230,387,1286,Methyl Aminolevulinate Hydrochloride,COC(=O)CCC(=O)CN,Liver disorder,Rat,-1.6989700043360187,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 021415/S-000, page:58 PDF 5673k",https://www.pharmapendium.com/browse/fda/Methyl Aminolevulinate Hydrochloride/4112911d986c9dd245c7a180974b9cf0?reference=58,2002.0
231,388,1287,Methyl Tert-Butyl Ether,COC(C)(C)C,Liver disorder,Rat,-2.4216039268698317,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicological Sciences 71,31,2003   ---   ISSN:1096-6080   JOURNAL:Toxicological Sciences   PAGES:31   VOLUME:71",,2003.0
232,389,1289,Methylene Blue,CN(C)C1=CC2=C(C=C1)N=C1C=CC(=[N+](C)C)C=C1S2,Liver disorder,Mouse,-2.6087933739869307,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/CHMP/424242/2020; EMEA/H/C/002776/0000, page:41 PDF 3305k",https://www.pharmapendium.com/browse/ema/Methylene Blue/544e50d7b00d00caa2b6e1781a475c1f?reference=41,2020.0
233,390,1293,Methylnaltrexone Bromide,C[N+]1(CC2CC2)CCC23C4=C5OC2C(=O)CCC3(O)C1CC4=CC=C5O,Liver disorder,Rat,-2.848189116991399,Repeated,Oral,"FDA approval package document: Pharmacology Review 021964/S-000 Part 02, page:42 PDF 5240k",https://www.pharmapendium.com/browse/fda/Methylnaltrexone Bromide/27c637bf2c53b65948b61cd3cf377771?reference=42,2008.0
234,391,1298,Methyltestosterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C1CCC2(C)O,Liver disorder,Rat,-1.3617278360175928,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologist 66,276,2002   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:276   VOLUME:66",,2002.0
235,394,1303,Mexiletine Hydrochloride,CC1=C(OCC(C)N)C(C)=CC=C1,Liver disorder,Rat,-2.0,Repeated,Oral,"FDA approval package document: Approval Package 018873/S-007, S-009, S-010, S-013, S-005, S-002, S-003, S-014 Part 02, page:7 PDF 7590k",https://www.pharmapendium.com/browse/fda/Mexiletine Hydrochloride/bec2e470c210bb626a331d0ebb6e3e6e?reference=7,1988.0
236,397,1320,Midodrine Hydrochloride,COC1=CC=C(OC)C(C(O)CNC(=O)CN)=C1,Liver disorder,Rat,-1.1760912590556811,Repeated,Intragastric,"FDA approval package document: Pharmacology Review 019815, page:29 PDF 2720k",https://www.pharmapendium.com/browse/fda/Midodrine Hydrochloride/f3b210f7e156784caab9e74e34b1676c?reference=29,1990.0
237,398,1322,Mifepristone,CC#CC1(O)CCC2C3=C(C4=C(CC3)CC(=O)CC4)C(C3=CC=C(N(C)C)C=C3)CC21C,Liver disorder,Rat,-2.005395031886706,Repeated,Oral,"FDA approval package document: Pharmacology Review 202107/S-000 Part 04, page:25 PDF 7149k",https://www.pharmapendium.com/browse/fda/Mifepristone/3462b48517ccc84185c9dd06f991e8f1?reference=25,2012.0
238,399,1326,Miglustat,CCCCN1CC(O)C(O)C(O)C1CO,Liver disorder,Mouse,-3.141911630920288,Repeated,Oral,"FDA approval package document: Pharmacology Review 021348/S-000 Part 01, page:35 PDF 1250k",https://www.pharmapendium.com/browse/fda/Miglustat/c6a2b7752cd599c68628190dc5d18ae6?reference=35,2003.0
239,401,1348,Miltefosine,CCCCCCCCCCCCCCCCOP(=O)([O-])OCC[N+](C)(C)C,Liver disorder,Rat,-0.6989700043360189,Repeated,Oral,"FDA approval package document: Pharmacology Review 204684/S-000 Part 02, page:11 PDF 335k",https://www.pharmapendium.com/browse/fda/Miltefosine/ce0de14473507b05f8d9047be3725f66?reference=11,2013.0
240,402,1349,Minocycline Hydrochloride,CN(C)C1=CC=C(O)C2=C1CC1CC3C(N(C)C)C(=O)C(C(N)=O)C(=O)C3(O)C(=O)C1C2=O,Liver disorder,Mouse,-1.4471580313422192,Repeated,Oral,Reference from PharmaPendium Published Toxicity: E-368883728   ---   DOI:10.1016/j.ijbiomac.2013.04.011   ISSN:0141-8130   JOURNAL:International Journal of Biological Macromolecules   PAGES:20   VOLUME:59,http://dx.doi.org/10.1016/j.ijbiomac.2013.04.011,2013.0
241,403,1350,Minoxidil,NC1=CC(N2CCCCC2)=NC(N)=[N+]1[O-],Liver disorder,Rat,-1.649983543645145,Repeated,Topical,"FDA approval package document: Pharmacology Review 021812/S-000, page:19 PDF 1628k",https://www.pharmapendium.com/browse/fda/Minoxidil/ec1a9dc09fffb0e1e912162324b2ec31?reference=19,2005.0
242,404,1359,Mirabegron,NC1=NC(CC(=O)NC2=CC=C(CCNCC(O)C3=CC=CC=C3)C=C2)=CS1,Liver disorder,Rabbit,-1.6020599913279625,Repeated,Oral,"FDA approval package document: Pharmacology Review 202611/S-000 Part 06, page:24 PDF 15412k",https://www.pharmapendium.com/browse/fda/Mirabegron/ef06749c9857f9b7b3903c7e9bdd46b6?reference=24,2012.0
243,405,1361,Mirtazapine,CN1CCN2C3=C(C=CC=N3)CC3=CC=CC=C3C2C1,Liver disorder,Rat,-1.845098040014257,Repeated,Intraperitoneal,"FDA approval package document: Pharmacology Review 020415 Part 04, page:1 PDF 1075k",https://www.pharmapendium.com/browse/fda/Mirtazapine/bd430d46783dca00cb57d089c63ba7c9?reference=1,1990.0
244,406,1363,Mitoxantrone Hydrochloride,OCCN=CCNC1=CC=C(NCCNCCO)C2=C1C(O)=C1C(O)=CC=C(O)C1=C2O,Liver disorder,Mouse,-0.9030899869919436,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: E-602180173   ---   DOI:10.1016/j.tox.2015.01.006   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:106   VOLUME:329,http://dx.doi.org/10.1016/j.tox.2015.01.006,2015.0
245,410,1376,Monomethyl Fumarate,COC(=O)/C=C/C(=O)O,Liver disorder,Rat,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 210296/S-000, page:11 PDF 3988k",https://www.pharmapendium.com/browse/fda/Monomethyl Fumarate/9f3241670d6c72beab35d59cf5b64fca?reference=11,2018.0
246,411,1377,Monosodium L-Glutamate,NC(CCC(=O)O)C(=O)O,Liver disorder,Mouse,-3.93597934219487,Repeated,Subcutaneous,"Reference from PharmaPendium Published Toxicity: Toxicology 219,97,2006   ---   DOI:10.1016/J.TOX.2005.11.014   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:97   VOLUME:219",http://dx.doi.org/10.1016/J.TOX.2005.11.014,2006.0
247,412,1385,Moricizine Hydrochloride,CCOC(=O)NC1=CC=C2SC3=C(C=CC=C3)N(C(=O)CCN3CCOCC3)C2=C1,Liver disorder,Rat,-1.8854640237914675,Repeated,Oral,"FDA approval package document: Approval Package 019753 Part 08, page:26 PDF 6073k",https://www.pharmapendium.com/browse/fda/Moricizine Hydrochloride/5fa50b49c903de171ecfe837ec47d078?reference=26,1990.0
248,413,1397,Morphine Sulfate,CN1CCC23C4=C5C=CC(O)=C4OC2C(O)C=CC3C1C5,Liver disorder,Rabbit,-1.4771212547196624,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 208603/S-000 Part 02, page:14 PDF 1392k",https://www.pharmapendium.com/browse/fda/Morphine Sulfate/fb6ef3e78b3ab404af7b3297d076f73f?reference=14,2016.0
249,415,1402,Mupirocin,CC(=CC(=O)OCCCCCCCCC(=O)O)CC1OCC(CC2OC2C(C)C(C)O)C(O)C1O,Liver disorder,Rat,-2.0,Repeated,Subcutaneous,"FDA approval package document: Approval Package 050591 Part 01, page:56 PDF 4968k",https://www.pharmapendium.com/browse/fda/Mupirocin/e830c6926fbd6fbf2959364625ce36fe?reference=56,1986.0
250,416,1403,Mycophenolic Acid,COC1=C(C)C2=COC(O)=C2C(O)=C1C/C=C(\C)CCC(=O)O,Liver disorder,Rat,-1.2787536009528289,Repeated,Oral,"FDA approval package document: Pharmacology Review 050791/S-000, page:30 PDF 1414k",https://www.pharmapendium.com/browse/fda/Mycophenolic Acid/3dd1614b8545a338d2f78969f7067a46?reference=30,2004.0
251,417,1405,Nabumetone,COC1=CC2=CC=C(CCC(C)=O)C=C2C=C1,Liver disorder,Rat,-2.420615770625765,Repeated,Oral,"FDA approval package document: Approval Package 019583/S-011 Part 05, page:60 PDF 5593k",https://www.pharmapendium.com/browse/fda/Nabumetone/a8308c0dca40df6b25e79e1fdb346fa6?reference=60,1995.0
252,418,1410,Naftifine Hydrochloride,CN(C/C=C/C1=CC=CC=C1)CC1=CC=CC2=CC=CC=C12,Liver disorder,Rat,-2.2730012720637376,Repeated,Oral,"FDA approval package document: Pharmacology Review 204286/S-000, page:13 PDF 2989k",https://www.pharmapendium.com/browse/fda/Naftifine Hydrochloride/b3a893386c672bfcd0bef846c00d2729?reference=13,2012.0
253,419,1412,Nalmefene Hydrochloride,C=C1CCC2(O)C3CC4=C5C(=C(O)C=C4)OC1C52CCN3CC1CC1,Liver disorder,Rat,-1.0413926851582251,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 020459 Part 01, page:27 PDF 1013k",https://www.pharmapendium.com/browse/fda/Nalmefene Hydrochloride/d8936bb82bf2e915ef8ae5ff18e7e04c?reference=27,1995.0
254,420,1413,Naloxegol Oxalate,C=CCN1CCC23C4=C5C=CC(O)=C4OC2C(OCCOCCOCCOCCOCCOCCOCCOC)CCC3(O)C1C5,Liver disorder,Rat,-2.720159303405957,Repeated,Oral,"FDA approval package document: Pharmacology Review 204760/S-000, page:258 PDF 33475k",https://www.pharmapendium.com/browse/fda/Naloxegol Oxalate/170cfe085c4dee733a6c9749a490c3d8?reference=258,2009.0
255,421,1417,Naloxone Hydrochloride,C=CCN1CCC23C4=C5OC2C(=O)CCC3(O)C1CC4=CC=C5O,Liver disorder,Mouse,-6.778151250383644,Repeated,Intraperitoneal,"Reference from PharmaPendium Published Toxicity: Toxicology 251,35,2008   ---   DOI:10.1016/j.tox.2008.07.051   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:35   VOLUME:251",http://dx.doi.org/10.1016/j.tox.2008.07.051,2008.0
256,422,1418,Naltrexone Hydrochloride,O=C1CCC2(O)C3CC4=C5C(=C(O)C=C4)OC1C52CCN3CC1CC1,Liver disorder,Rat,-2.633468455579586,Repeated,Subcutaneous,"FDA approval package document: Approval Package 018932/S-001, S-010, S-012 Part 04, page:49 PDF 5235k",https://www.pharmapendium.com/browse/fda/Naltrexone Hydrochloride/33501fc8822e8534ebc3a04462bec599?reference=49,1984.0
257,423,1420,Nandrolone Decanoate,CCCCCCCCCC(=O)OC1CCC2C3CC=C4CC(=O)CCC4C3CCC12C,Liver disorder,Rat,-1.548184610545108,Repeated,Intramuscular,Reference from PharmaPendium Published Toxicity: 600033568   ---   DOI:10.1371/journal.pone.0102699   ISSN:1932-6203   JOURNAL:PLoS ONE   PAGES:e102699   VOLUME:9,http://dx.doi.org/10.1371/journal.pone.0102699,2014.0
258,424,1423,Nandrolone Phenpropionate,CC12CCC3C4=C(CCC3C1CCC2OC(=O)CCC1=CC=CC=C1)CC(=O)CC4,Liver disorder,Rat,-1.0791812460476249,Repeated,Subcutaneous,"Reference from PharmaPendium Published Toxicity: Steroids 18,731,1971   ---   DOI:10.1016/0039-128X(71)90032-8   ISSN:0039-128X   JOURNAL:Steroids   PAGES:731   VOLUME:18",http://dx.doi.org/10.1016/0039-128X(71)90032-8,1971.0
259,425,1424,Naratriptan Hydrochloride,CNS(=O)(=O)CCC1=CC=C2NC=C(C3CCN(C)CC3)C2=C1,Liver disorder,Rat,-2.531478917042255,Repeated,Oral,"FDA approval package document: Pharmacology Review 020763, page:26 PDF 1371k",https://www.pharmapendium.com/browse/fda/Naratriptan Hydrochloride/d3a5f3783b4ce1847618be65e184eca3?reference=26,1997.0
260,426,1426,Natamycin,CC1C/C=C/C=C/C=C/C=C/C(OC2OC(C)C(O)C(N)C2O)CC2OC(O)(CC(O)CC3OC3=CCC(=O)O1)CC(O)C2C(=O)O,Liver disorder,Rat,-0.7781512503836436,Repeated,Oral,Reference from PharmaPendium Published Toxicity: E-369860672   ---   DOI:10.1016/j.fct.2013.08.075   ISSN:0278-6915   JOURNAL:Food and Chemical Toxicology   PAGES:281   VOLUME:62,http://dx.doi.org/10.1016/j.fct.2013.08.075,2013.0
261,427,1427,Nateglinide,CC(C)C1CCC(C(=O)NC(CC2=CC=CC=C2)C(=O)O)CC1,Liver disorder,Rat,-2.423245873936808,Repeated,Oral,"FDA approval package document: Pharmacology Review 021204/S-000 Part 01, page:38 PDF 1737k",https://www.pharmapendium.com/browse/fda/Nateglinide/5182d7a62b279a505cac90073f473f47?reference=38,2000.0
262,429,1431,Nedocromil Sodium,CCCC1=C2C(=CC3=C1OC(C(=O)O)=CC3=O)C(=O)C=C(C(=O)O)N2CC,Liver disorder,Rat,-1.5563025007672873,Repeated,Inhalation,"FDA approval package document: Approval Package 019660/S-003, S-010, S-015 Part 18, page:9 PDF 7412k",https://www.pharmapendium.com/browse/fda/Nedocromil Sodium/9a4a5dc434602f78451d3ed808584018?reference=9,1993.0
263,431,1433,Nelfinavir Mesylate,CC1=C(O)C=CC=C1C(=O)NC(CSC1=CC=CC=C1)C(O)CN1CC2CCCCC2CC1C(=O)NC(C)(C)C,Liver disorder,Rat,-3.0256130404386536,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Human & Experimental Toxicology 24,643,2005   ---   DOI:10.1191/0960327105ht568oa   JOURNAL:Human and Experimental Toxicology   PAGES:643   VOLUME:24",http://dx.doi.org/10.1191/0960327105ht568oa,2005.0
264,432,1437,Nepafenac,NC(=O)CC1=CC=CC(C(=O)C2=CC=CC=C2)=C1N,Liver disorder,Rat,-1.1760912590556811,Repeated,Oral,"FDA approval package document: Pharmacology Review 021862/S-000, page:64 PDF 5867k",https://www.pharmapendium.com/browse/fda/Nepafenac/d2d477d96712312b2808b94aae3b0c0d?reference=64,2005.0
265,433,1440,Netarsudil Dimesylate,CC1=CC(C)=C(C(=O)OCC2=CC=C(C(CN)C(=O)NC3=CC=C4C=NC=CC4=C3)C=C2)C=C1,Liver disorder,Rat,-0.3010299956639812,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 208254/S-000, page:67 PDF 12472k",https://www.pharmapendium.com/browse/fda/Netarsudil Dimesylate/3e18fe0da382d2aa093aa945b7f3774c?reference=67,2016.0
266,434,1442,Nevirapine,CC1=CC=NC2=C1NC(=O)C1=C(N=CC=C1)N2C1CC1,Liver disorder,Rat,-1.235528446907549,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: 365295535   ---   DOI:10.1177/0960327111424304   ISSN:0960-3271   JOURNAL:Human and Experimental Toxicology   PAGES:676   VOLUME:31,http://dx.doi.org/10.1177/0960327111424304,2012.0
267,435,1448,Niacin,O=C(O)C1=CC=CN=C1,Liver disorder,Mouse,-1.1760912590556811,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 2005983045   ---   DOI:10.1016/j.bbalip.2020.158731   ISSN:1388-1981   JOURNAL:Biochimica et Biophysica Acta - Molecular and Cell Biology of Lipids   PAGES:158731   VOLUME:1865,http://dx.doi.org/10.1016/j.bbalip.2020.158731,2020.0
268,436,1449,Nicardipine Hydrochloride,COC(=O)C1=C(C)N=C(C)C(C(=O)OCCN(C)CC2=CC=CC=C2)C1C1=CC([N+](=O)[O-])=CC=C1,Liver disorder,Rat,-1.608793373986931,Repeated,Oral,"FDA approval package document: Approval Package 019488 Part 05, page:46 PDF 4805k",https://www.pharmapendium.com/browse/fda/Nicardipine Hydrochloride/dbacf098f277f16a297064e8da59d2db?reference=46,1988.0
269,437,1458,Nicotine,CN1CCCC1C1=CC=CN=C1,Liver disorder,Rat,-1.3925616800980352,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 50964942   ---   DOI:10.1016/j.etp.2010.05.013   ISSN:0940-2993   JOURNAL:Experimental and Toxicologic Pathology   PAGES:15   VOLUME:64,http://dx.doi.org/10.1016/j.etp.2010.05.013,2012.0
270,438,1472,Nifedipine,COC(=O)C1=C(C)N=C(C)C(C(=O)OC)C1C1=CC=CC=C1[N+](=O)[O-],Liver disorder,Mouse,-1.1760912590556811,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 600225479   ---   ISSN:0976-044X   JOURNAL:International Journal of Pharmaceutical Sciences Review and Research   PAGES:210   VOLUME:28,,2014.0
271,439,1473,Nifurtimox,CC1CS(=O)(=O)CCN1/N=C/C1=CC=C([N+](=O)[O-])O1,Liver disorder,Rat,-1.3979400086720375,Repeated,Oral,"FDA approval package document: Approval Package 213464/S-000 Part 03, page:3 PDF 560k",https://www.pharmapendium.com/browse/fda/Nifurtimox/16aef1b3829fd18b40e97ebbbb856c36?reference=3,2020.0
272,442,1476,Nimodipine,COCCOC(=O)C1=C(C)N=C(C)C(C(=O)OC(C)C)C1C1=CC([N+](=O)[O-])=CC=C1,Liver disorder,Mouse,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 018869/S-005, S-001 Part 04, page:29 PDF 9930k",https://www.pharmapendium.com/browse/fda/Nimodipine/db8c2510709852928c53687ef6cde03e?reference=29,1988.0
273,443,1478,Nintedanib Esylate,COC(=O)C1=CC2=C(C=C1)C(C(=NC1=CC=C(N(C)C(=O)CN3CCN(C)CC3)C=C1)C1=CC=CC=C1)=C(O)N2,Liver disorder,Mouse,-1.5593080109070123,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/726072/2014; EMEA/H/C/002569/0000, page:30 PDF 4338k",https://www.pharmapendium.com/browse/ema/Nintedanib Esylate/4d2bdecfb76188888c3a745b6ec6b8c5?reference=30,2014.0
274,444,1486,Nisoldipine,COC(=O)C1=C(C)N=C(C)C(C(=O)OCC(C)C)C1C1=CC=CC=C1[N+](=O)[O-],Liver disorder,Mouse,-0.6020599913279624,Repeated,Oral,"FDA approval package document: Pharmacology Review 020356 Part 01, page:69 PDF 3859k",https://www.pharmapendium.com/browse/fda/Nisoldipine/2644cfb5247cc1efed4e06560f614b15?reference=69,1994.0
275,445,1487,Nitazoxanide,CC(=O)OC1=CC=CC=C1C(=O)NC1=NC=C([N+](=O)[O-])S1,Liver disorder,Rat,-3.380211241711606,Repeated,Oral,"FDA approval package document: Pharmacology Review 021818/S-000; 021498/S-003, page:48 PDF 4554k",https://www.pharmapendium.com/browse/fda/Nitazoxanide/1689c2def7a3ad1b1589196c3300e3d4?reference=48,2005.0
276,447,1491,Nitric Oxide,[N]=O,Liver disorder,Rat,-0.8450980400142568,Repeated,Inhalation,"Reference from PharmaPendium Published Toxicity: Gigiena Truda i Professional'nye Zabolevaniya 19(4),52,1975   ---   JOURNAL:Gigiena Truda i Professional'nye Zabolevaniya   PAGES:52   VOLUME:19",,1975.0
277,448,1492,Nitroglycerin,O=[N+]([O-])OCC(CO[N+](=O)[O-])O[N+](=O)[O-],Liver disorder,Rat,-2.5599066250361124,Repeated,Oral,"FDA approval package document: Pharmacology Review 021359/S-000, page:32 PDF 8968k",https://www.pharmapendium.com/browse/fda/Nitroglycerin/bf82c8bde9897de9094f6c6a1715d523?reference=32,2010.0
278,450,1494,Nystatin,CC1/C=C/C=C/CC/C=C/C=C/C=C/C=C/C(OC2OC(C)C(O)C(N)C2O)CC2OC(O)(CC(O)C(O)CCC(O)CC(O)CC(O)CC(=O)OC(C)C(C)C1O)CC(O)C2C(=O)O,Liver disorder,Rat,-0.9420080530223132,Repeated,Intravenous,Reference from PharmaPendium Published Toxicity: nystatin421   ---   DOI:10.1093/toxsci/53.2.421   JOURNAL:Toxicological Sciences   PAGES:421   VOLUME:53,http://dx.doi.org/10.1093/toxsci/53.2.421,2000.0
279,451,1498,Obeticholic Acid,CCC1C(O)C2C3CCC(C(C)CCC(=O)O)C3(C)CCC2C2(C)CCC(O)CC12,Liver disorder,Mouse,-1.9030899869919435,Repeated,Oral,"FDA approval package document: Pharmacology Review 207999/S-000 Part 03, page:21 PDF 13571k",https://www.pharmapendium.com/browse/fda/Obeticholic Acid/a2a2a577ec5b639dc211430b2c08567e?reference=21,2016.0
280,452,1504,Octreotide Acetate,CC(O)C(CO)NC(=O)C1CSSCC(NC(=O)C(N)CC2=CC=CC=C2)C(=O)NC(CC2=CC=CC=C2)C(=O)NC(CC2=CNC3=C2C=CC=C3)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N1,Liver disorder,Rat,-0.6368220975871743,Repeated,Intramuscular,"FDA approval package document: Pharmacology Review 021008, page:15 PDF 1109k",https://www.pharmapendium.com/browse/fda/Octreotide Acetate/62a5f9577549d516dd40d48aee2b5986?reference=15,1998.0
281,453,1507,Octyl Methoxycinnamate,CCCCC(CC)COC(=O)/C=C/C1=CC=C(OC)C=C1,Liver disorder,Rat,-0.6989700043360189,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicology 238,192,2007   ---   DOI:10.1016/J.TOX.2007.06.088   ISSN:0300-483X   JOURNAL:Toxicology   PAGES:192   VOLUME:238",http://dx.doi.org/10.1016/J.TOX.2007.06.088,2007.0
282,454,1509,Olanzapine,CC1=CC2=C(NC3=CC=CC=C3N=C2N2CCN(C)CC2)S1,Liver disorder,Rat,-0.8325089127062363,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 51806995   ---   DOI:10.1007/s00213-011-2555-2   ISSN:0033-3158   JOURNAL:Psychopharmacology   PAGES:155   VOLUME:221,http://dx.doi.org/10.1007/s00213-011-2555-2,2012.0
283,456,1522,Oliceridine fumarate,COC1=C(CNCCC2(C3=NC=CC=C3)CCOC3(CCCC3)C2)SC=C1,Liver disorder,Rat,-1.0791812460476249,Repeated,Intravenous,"FDA approval package document: Approval Package 210730/S-000 Part 20, page:42 PDF 8197k",https://www.pharmapendium.com/browse/fda/Oliceridine fumarate/ad395b687bf93dc34e0769b2783cfd69?reference=42,2018.0
284,457,1523,Olmesartan Medoxomil,CCCC1=NC(C(C)(C)O)=C(C(=O)OC2=C(C)OC(=O)O2)N1CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1,Liver disorder,Rat,-3.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 021286/S-000 Part 03, page:25 PDF 1456k",https://www.pharmapendium.com/browse/fda/Olmesartan Medoxomil/21fb6fdae83221b4fff6753825335b55?reference=25,2001.0
285,458,1524,Olodaterol Hydrochloride,COC1=CC=C(CC(C)(C)NCC(O)C2=C3OCC(=O)NC3=CC(O)=C2)C=C1,Liver disorder,Rat,-8.459392487759231,Repeated,Inhalation,"FDA approval package document: Pharmacology Review 203108/S-000 Part 10, page:96 PDF 18929k",https://www.pharmapendium.com/browse/fda/Olodaterol Hydrochloride/afce8ee34becde92731f4a1d28cfe49a?reference=96,2012.0
286,459,1525,Olopatadine Hydrochloride,CN(C)CC/C=C1/C2=CC=CC=C2COC2=CC=C(CC(=O)O)C=C12,Liver disorder,Rat,-2.195207549502754,Repeated,Intranasal,"FDA approval package document: Pharmacology Review 021861/S-000 Part 04, page:30 PDF 630k",https://www.pharmapendium.com/browse/fda/Olopatadine Hydrochloride/cf9338734f621827d082aa13ba80fb5a?reference=30,2008.0
287,460,1529,Omacetaxine Mepesuccinate,COC(=O)CC(O)(CCCC(C)(C)O)C(=O)OC1C(OC)=CC23CCCN2CCC2=CC4=C(C=C2C13)OCO4,Liver disorder,Mouse,-2.7671558660821804,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 203585/S-000 Part 05, page:34 PDF 8962k",https://www.pharmapendium.com/browse/fda/Omacetaxine Mepesuccinate/a070c7ba71630a14ca9434d613ccefa8?reference=34,2012.0
288,461,1530,Omeprazole,COC1=CC=C2NC([S+]([O-])CC3=NC=C(C)C(OC)=C3C)=NC2=C1,Liver disorder,Rat,-2.0588054866759067,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: 365132694   ---   DOI:10.2131/jts.37.491   ISSN:1880-3989   JOURNAL:Journal of Toxicological Sciences   PAGES:491   VOLUME:37,http://dx.doi.org/10.2131/jts.37.491,2012.0
289,462,1534,Omeprazole Magnesium,COC1=CC2=C(C=C1)NC([S+]([O-])CC1=C(C)C(OC)=C(C)C=N1)=N2,Liver disorder,Rat,-1.8920946026904804,Repeated,Oral,"FDA approval package document: Pharmacology Review 022056/S-000, page:19 PDF 2607k",https://www.pharmapendium.com/browse/fda/Omeprazole Magnesium/195cbf09eb4d0b4fdcc4d00e4a3edcca?reference=19,2007.0
290,465,1541,Orlistat,CCCCCCCCCCCC(CC1OC(=O)C1CCCCCC)OC(=O)C(CC(C)C)NC=O,Liver disorder,Rat,-2.3090976174120144,Repeated,Oral,"FDA approval package document: Pharmacology Review 020766/S-000 Part 05, page:8 PDF 780k",https://www.pharmapendium.com/browse/fda/Orlistat/72e8a579f230ef5ddff24ca06a7344e5?reference=8,1999.0
291,466,1545,Orphenadrine Citrate,CC1=CC=CC=C1C(OCCN(C)C)C1=CC=CC=C1,Liver disorder,Rat,-0.4771212547196624,Repeated,Intraperitoneal,"Reference from PharmaPendium Published Toxicity: British Journal of Pharmacology 139,787,2003   ---   DOI:10.1038/SJ.BJP.0705305   ISSN:0007-1188   JOURNAL:British Journal of Pharmacology   PAGES:787   VOLUME:139",http://dx.doi.org/10.1038/SJ.BJP.0705305,2003.0
292,471,1564,Oxcarbazepine,NC(=O)N1C2=CC=CC=C2CC(=O)C2=CC=CC=C21,Liver disorder,Rat,-2.601961276818638,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 605769484   ---   DOI:10.1124/dmd.115.063370   ISSN:0090-9556   JOURNAL:Drug Metabolism and Disposition   PAGES:958   VOLUME:43,http://dx.doi.org/10.1124/dmd.115.063370,2015.0
293,473,1579,Oxybutynin Chloride,CCN(CC)CC#CCOC(=O)C(O)(C1=CC=CC=C1)C1CCCCC1,Liver disorder,Rat,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 020897/S-000, page:15 PDF 1859k",https://www.pharmapendium.com/browse/fda/Oxybutynin Chloride/117c34c362af3bb608995803fb9328cd?reference=15,1998.0
294,474,1580,Oxymetazoline Hydrochloride,CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1,Liver disorder,Rabbit,-1.0791812460476249,Repeated,Subcutaneous,"FDA approval package document: Approval Package 019407 Part 02, page:32 PDF 2443k",https://www.pharmapendium.com/browse/fda/Oxymetazoline Hydrochloride/3e60a88993296b946c89f24a6d4cebdf?reference=32,1989.0
295,475,1582,Oxymorphone Hydrochloride,CN1CCC23C4=C5C=CC(O)=C4OC2C(=O)CCC3(O)C1C5,Liver disorder,Rat,-1.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 021611/S-000; 021610/S-000 Part 04, page:61 PDF 6258k",https://www.pharmapendium.com/browse/fda/Oxymorphone Hydrochloride/a343e070725356f22663e148eecbbab8?reference=61,2003.0
296,476,1584,Oxytetracycline Hydrochloride,CN(C)C1C(=O)C(C(N)=O)C(=O)C2(O)C(=O)C3C(=O)C4=C(C=CC=C4O)C(C)(O)C3C(O)C12,Liver disorder,Mouse,-1.1760912590556811,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Fundamental and Applied Toxicology 7,434,1986   ---   DOI:10.1016/0272-0590(86)90093-X   ISSN:0272-0590   JOURNAL:Fundamental and Applied Toxicology   PAGES:434   VOLUME:7",http://dx.doi.org/10.1016/0272-0590(86)90093-X,1986.0
297,477,1586,Paclitaxel,CC(=O)OC1=C2C(C)C(OC(=O)C(O)C(NC(=O)C3=CC=CC=C3)C3=CC=CC=C3)CC(O)(C(OC(=O)C3=CC=CC=C3)C3C4(OC(C)=O)COC4CC(O)C3(C)C1=O)C2(C)C,Liver disorder,Rat,-0.8846065812979305,Repeated,Intraperitoneal,"FDA approval package document: Approval Package 020262 Part 03, page:25 PDF 5477k",https://www.pharmapendium.com/browse/fda/Paclitaxel/ff3e75f75d8129aa72b46b11da8f1a26?reference=25,1992.0
298,478,1590,Palbociclib,CC(=O)C1=C(C)C2=CN=C(NC3=CC=C(N4CCNCC4)C=N3)N=C2N(C2CCCC2)C1=O,Liver disorder,Rat,-2.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 207103/S-000 Part 04, page:76 PDF 9073k",https://www.pharmapendium.com/browse/fda/Palbociclib/c5e16bbd7f3aec0f4b17735224900ef5?reference=76,2014.0
299,480,1594,Palonosetron Hydrochloride,O=C1C2=CC=CC3=C2C(CCC3)CN1C1CN2CCC1CC2,Liver disorder,Rat,-1.9867717342662448,Repeated,Oral,"EMA approval document: Scientific Discussion, page:14 PDF 548k",https://www.pharmapendium.com/browse/ema/Palonosetron Hydrochloride/21048cb626825fd07de06f8550d0b5af?reference=14,2011.0
300,481,1603,Pamidronate Disodium,NCCC(O)([PH](=O)(=O)O)[PH](=O)(=O)O,Liver disorder,Rat,-0.7781512503836436,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 020036/S-000, page:17 PDF 1638k",https://www.pharmapendium.com/browse/fda/Pamidronate Disodium/9f0eea24087acc6b83e013ae01f9de8a?reference=17,1993.0
301,483,1627,Paricalcitol,CC(/C=C/C(C)C(C)(C)O)C1CCC2/C(=C/C=C3CC(O)CC(O)C3)CCCC21C,Liver disorder,Rat,-6.698970004336019,Repeated,Intravenous,"FDA approval package document: Administrative documents 020819, page:18 PDF 721k",https://www.pharmapendium.com/browse/fda/Paricalcitol/88ad788139f42ee77fcb99d627fd81bc?reference=18,1997.0
302,486,1630,Pasireotide Diaspartate,NCCCCC1NC(=O)C(CC2=CNC3=C2C=CC=C3)NC(=O)C(C2=CC=CC=C2)NC(=O)C2CC(OC(=O)NCCN)CN2C(=O)C(CC2=CC=CC=C2)NC(=O)C(CC2=CC=C(OCC3=CC=CC=C3)C=C2)NC1=O,Liver disorder,Mouse,-0.6320232147054056,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 200677/S-000 Part 05, page:18 PDF 6142k",https://www.pharmapendium.com/browse/fda/Pasireotide Diaspartate/4ed6019c19a5222ed4229ab5540ce31f?reference=18,2012.0
303,487,1638,Pazopanib Hydrochloride,CC1=CC=C(NC2=NC=CC(N(C)C3=CC4=NN(C)C(C)=C4C=C3)=N2)C=C1S(N)(=O)=O,Liver disorder,Rat,-2.5642714304385628,Repeated,Oral,"FDA approval package document: Pharmacology Review 022465/S-000, page:171 PDF 5342k",https://www.pharmapendium.com/browse/fda/Pazopanib Hydrochloride/647550e4d51c0844ca0839d4a13db869?reference=171,2009.0
304,488,1641,Pemirolast Potassium,CC1=CC=CN2C(=O)C(C3=NNN=N3)=CN=C12,Liver disorder,Rat,-2.2081725266671217,Repeated,Oral,"FDA approval package document: Approval Package 021079/S-000, page:144 PDF 6666k",https://www.pharmapendium.com/browse/fda/Pemirolast Potassium/31b625018776df73243ebf5ef61795a6?reference=144,1999.0
305,489,1643,Penicillamine,CC(C)(S)C(N)C(=O)O,Liver disorder,Rat,-3.035189508908448,Repeated,Oral,"FDA approval package document: Approval Package 050491 Part 01, page:42 PDF 5024k",https://www.pharmapendium.com/browse/fda/Penicillamine/f4eac439c72373bbc74fda5c16f8e622?reference=42,1978.0
307,491,1649,Pentetrazol,C1CCC2=NN=NN2CC1,Liver disorder,Mouse,-1.1760912590556811,Repeated,Intraperitoneal,"Reference from PharmaPendium Published Toxicity: Clinical and Experimental Pharmacology and Physiology 32,579,2005   ---   ISSN:0305-1870   JOURNAL:Clinical and Experimental Pharmacology and Physiology   PAGES:579   VOLUME:32",,2005.0
308,492,1650,Pentobarbital Sodium,CCCC(C)C1(CC)C(=O)NC(=O)NC1=O,Liver disorder,Rat,-0.6020599913279624,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Fundamental and Applied Toxicology 4,261,1984   ---   DOI:10.1016/0272-0590(84)90127-1   ISSN:0272-0590   JOURNAL:Fundamental and Applied Toxicology   PAGES:261   VOLUME:4",http://dx.doi.org/10.1016/0272-0590(84)90127-1,1984.0
309,493,1651,Pentoxifylline,CC(=O)CCCCN1C(=O)C2=C(N=CN2C)N(C)C1=O,Liver disorder,Rat,-0.6368220975871743,Repeated,Parenteral,"Reference from PharmaPendium Published Toxicity: Toxicologist 44,16,2005   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:16   VOLUME:44",,2005.0
310,494,1654,Peramivir,CCC(CC)C(NC(C)=O)C1C(N=C(N)N)CC(C(=O)O)C1O,Liver disorder,Rabbit,-2.4771212547196626,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 206426/S-000, page:50 PDF 16739k",https://www.pharmapendium.com/browse/fda/Peramivir/2e265b60dcbb27a240353dc075b92ddd?reference=50,2014.0
311,495,1655,Perampanel,N#CC1=CC=CC=C1C1=CC(C2=NC=CC=C2)=CN(C2=CC=CC=C2)C1=O,Liver disorder,Rat,-2.255272505103306,Repeated,Oral,"FDA approval package document: Pharmacology Review 202834/S-000 Part 07, page:24 PDF 2405k",https://www.pharmapendium.com/browse/fda/Perampanel/c579050cd85a73c52827e4eac0cc7489?reference=24,2012.0
312,497,1659,Pergolide Mesylate,CCCN1CC(CSC)CC2C3=C4C(=CNC4=CC=C3)CC21,Liver disorder,Mouse,-0.6532125137753437,Repeated,Oral,"FDA approval package document: Approval Package 019385 Part 02, page:44 PDF 6033k",https://www.pharmapendium.com/browse/fda/Pergolide Mesylate/f9d216f876775f3890aad904f920a7db?reference=44,1988.0
313,498,1661,Perindopril Erbumine,CCCC(NC(C)C(=O)N1C(C(=O)O)CC2CCCCC21)C(=O)OCC,Liver disorder,Rat,-1.8750612633917,Repeated,Oral,"FDA approval package document: Pharmacology Review 020184 Part 04, page:5 PDF 1049k",https://www.pharmapendium.com/browse/fda/Perindopril Erbumine/eecaca772fbd09ba69c13eb44518c45b?reference=5,1993.0
314,500,1669,Phenobarbital,CCC1(C2=CC=CC=C2)C(=O)NC(=O)NC1=O,Liver disorder,Mouse,-1.0258642040799246,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologist -,170,2008   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:170",,2008.0
315,501,1714,Phenytoin,O=C1NC(=O)C(C2=CC=CC=C2)(C2=CC=CC=C2)N1,Liver disorder,Mouse,-1.5984257066728682,Repeated,Multiple,Reference from PharmaPendium Published Toxicity: 370306826   ---   DOI:10.1093/toxsci/kft184   ISSN:1096-0929   JOURNAL:Toxicological Sciences   PAGES:250   VOLUME:136,http://dx.doi.org/10.1093/toxsci/kft184,2013.0
317,503,1718,Pilocarpine Hydrochloride,CCC1C(=O)OCC1CC1=CN=CN1C,Liver disorder,Mouse,-1.4771212547196624,Repeated,Oral,"FDA approval package document: Pharmacology Review 020237/S-007, page:5 PDF 617k",https://www.pharmapendium.com/browse/fda/Pilocarpine Hydrochloride/a113f647343db85fd9442b8008894480?reference=5,1997.0
318,505,1722,Pinacidil,CC(N=C(N=C1C=CNC=C1)NC#N)C(C)(C)C,Liver disorder,Rat,-0.6989700043360189,Repeated,Intravenous,"FDA approval package document: Approval Package 019456 Part 02, page:12 PDF 7731k",https://www.pharmapendium.com/browse/fda/Pinacidil/eb45457c772f0849c7279a847fc2a877?reference=12,1989.0
319,506,1723,Pindolol,CC(C)NCC(O)COC1=CC=CC2=C1C=CN2,Liver disorder,Rat,-2.113943352306837,Repeated,Oral,"FDA approval package document: Approval Package 018285/S-027 Part 03, page:34 PDF 7358k",https://www.pharmapendium.com/browse/fda/Pindolol/093f84fb76e31f30fe5995137e369dfe?reference=34,1982.0
320,507,1724,Pioglitazone Hydrochloride,CCC1=CN=C(CCOC2=CC=C(CC3=C(O)NC(=O)S3)C=C2)C=C1,Liver disorder,Rat,-1.7075701760979365,Repeated,Oral,"FDA approval package document: Pharmacology Review 021073/S-000 Part 02, page:6 PDF 745k",https://www.pharmapendium.com/browse/fda/Pioglitazone Hydrochloride/1986863bd8c3ff638f6b4e553adab37b?reference=6,1999.0
321,508,1728,Pirfenidone,CC1=CN(C2=CC=CC=C2)C(=O)C=C1,Liver disorder,Rat,-3.041392685158225,Repeated,Oral,"FDA approval package document: Pharmacology Review 022535/S-000 Part 09, page:47 PDF 6836k",https://www.pharmapendium.com/browse/fda/Pirfenidone/86762338ed5d64a5972433c703fdd84b?reference=47,2009.0
322,512,1747,Pralatrexate,C#CCC(CC1=NC2=C(N)N=C(N)N=C2N=C1)C1=CC=C(C(=O)NC(CCC(=O)O)C(=O)O)C=C1,Liver disorder,Rat,-0.3010299956639812,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 022468/S-000 Part 02, page:14 PDF 4689k",https://www.pharmapendium.com/browse/fda/Pralatrexate/328f8190a27f4869137f01c7415bf48a?reference=14,2009.0
323,514,1749,Pramipexole Dihydrochloride,CCCNC1CCC2=C(C1)SC(N)=N2,Liver disorder,Rat,1.013631348135158,Repeated,Oral,"FDA approval package document: Pharmacology Review 020667/S-000 Part 02, page:24 PDF 1178k",https://www.pharmapendium.com/browse/fda/Pramipexole Dihydrochloride/c4b6a224b10141b8c843c2fbc35f5a45?reference=24,1995.0
324,515,1754,Pramlintide Acetate,CCC(C)C(NC(=O)C1CCCN1C(=O)CNC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(CC1=CNC=N1)NC(=O)C(NC(=O)C(CC(C)C)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(CC(N)=O)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCC(N)=O)NC(=O)C(NC(=O)C(C)NC(=O)C1CSSCC(NC(=O)C(N)CCCCN)C(=O)NC(CC(N)=O)C(=O)NC(C(C)O)C(=O)NC(C)C(=O)NC(C(C)O)C(=O)N1)C(C)O)C(C)C)C(=O)NC(CC(C)C)C(=O)N1CCCC1C(=O)N1CCCC1C(=O)NC(C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NCC(=O)NC(CO)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CC1=CC=C(O)C=C1)C(N)=O)C(C)O)C(C)C)C(C)O,Liver disorder,Rat,-0.6989700043360189,Repeated,Subcutaneous,"FDA approval package document: Pharmacology Review 021332/S-000, page:40 PDF 5843k",https://www.pharmapendium.com/browse/fda/Pramlintide Acetate/dd29ef23d5ae31d8a3511d474b84f351?reference=40,2005.0
325,517,1766,Pravastatin Sodium,CCC(C)C(=O)OC1CC(O)C=C2C=CC(C)C(CCC(O)CC(O)CC(=O)O)C21,Liver disorder,Rat,-1.7256394326735374,Repeated,Oral,"FDA approval package document: Approval Package 019898/S-003, S-004, S-005, S-006, S-007, S-008, S-009, S-010, S-011, S-013, S-015, S-017, S-020 Part 03, page:46 PDF 4817k",https://www.pharmapendium.com/browse/fda/Pravastatin Sodium/a810d97b6db5279931007e1b16e75410?reference=46,1991.0
326,518,1772,Prednicarbate,CCOC(=O)OC1(C(=O)COC(=O)CC)CCC2C3CC=C4CC(=O)C=CC4(C)C3C(O)CC21C,Liver disorder,Rabbit,-2.5352941200427703,Repeated,Subcutaneous,"FDA approval package document: Approval Package 019568/S-003 Part 02, page:32 PDF 3886k",https://www.pharmapendium.com/browse/fda/Prednicarbate/8caa4eac839beb717b9e68c29d67f2ca?reference=32,1991.0
327,519,1775,Prednisolone,CC12C=CC(=O)C=C1CCC1C2C(O)CC2(C)C1CCC2(O)C(=O)CO,Liver disorder,Mouse,-1.4313637641589874,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 373029779   ---   DOI:10.2217/pgs.14.3   ISSN:1744-8042   JOURNAL:Pharmacogenomics   PAGES:629   VOLUME:15,http://dx.doi.org/10.2217/pgs.14.3,2014.0
328,520,1778,Pregabalin,CC(C)CC(CN)CC(=O)O,Liver disorder,Mouse,-3.22219604630172,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 365298107   ---   DOI:10.1093/toxsci/kfs146   ISSN:1096-6080   JOURNAL:Toxicological Sciences   PAGES:9   VOLUME:128,http://dx.doi.org/10.1093/toxsci/kfs146,2012.0
329,521,1781,Procarbazine Hydrochloride,CNNCC1=CC=C(C(=O)NC(C)C)C=C1,Liver disorder,Rat,-1.4471580313422192,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: 624004490   ---   DOI:10.1002/em.22227   ISSN:0893-6692   JOURNAL:Environmental and Molecular Mutagenesis   PAGES:56   VOLUME:60,http://dx.doi.org/10.1002/em.22227,2019.0
330,522,1783,Progesterone,CC(=O)C1CCC2C3CC=C4CC(=O)CCC4(C)C3CCC12C,Liver disorder,Rat,-1.1760912590556811,Repeated,Oral,"FDA approval package document: Approval Package 019781/S-000, page:35 PDF 1253k",https://www.pharmapendium.com/browse/fda/Progesterone/b21d494f346954d78a6e0899e1eee65b?reference=35,1989.0
331,523,1785,Promazine Hydrochloride,CN(C)CCCN1C2=CC=CC=C2SC2=C1C=CC=C2,Liver disorder,Rat,-0.6020599913279624,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologist 12,476,2008   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:476   VOLUME:12",,2008.0
332,524,1786,Propofol,CC(C)C1=CC=CC(C(C)C)=C1O,Liver disorder,Rabbit,-1.3010299956639813,Repeated,Parenteral,Reference from PharmaPendium Published Toxicity: 51365159   ---   DOI:10.1007/s11062-011-9174-8   ISSN:0090-2977   JOURNAL:Neurophysiology   PAGES:392   VOLUME:42,http://dx.doi.org/10.1007/s11062-011-9174-8,2011.0
333,525,1787,Propranolol Hydrochloride,CC(C)NCC(O)COC1=C2C=CC=CC2=CC=C1,Liver disorder,Rat,-1.6020599913279625,Repeated,Oral,"FDA approval package document: Pharmacology Review 205410/S-000, page:28 PDF 4609k",https://www.pharmapendium.com/browse/fda/Propranolol Hydrochloride/b90f2fbaeb0550dbe358d7e984b1eaac?reference=28,2013.0
334,526,1789,Propyl Alcohol,CCCO,Liver disorder,Rat,-1.954242509439325,Repeated,Inhalation,"Reference from PharmaPendium Published Toxicity: Vrednie chemichescie veshestva, galogen I kislorod sodergashie organicheskie soedinenia -,98,1994   ---   JOURNAL:Vrednie chemichescie veshestva. Galogen I kislorod sodergashie organicheskie soedinenia   PAGES:98",,1994.0
335,527,1790,Propylthiouracil,CCCC1=CC(=O)NC(=S)N1,Liver disorder,Rat,-0.9164539485499252,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologist 60,227,2001   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:227   VOLUME:60",,2001.0
336,528,1794,Pyrazinamide,NC(=O)C1=NC=CN=C1,Liver disorder,Rat,-4.271764185289855,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: 51921340   ---   DOI:10.1002/jat.2736   ISSN:0260-437X   JOURNAL:Journal of applied toxicology   PAGES:807   VOLUME:33,http://dx.doi.org/10.1002/jat.2736,2013.0
337,529,1797,Pyridostigmine Bromide,CN(C)C(=O)OC1=C[N+](C)=CC=C1,Liver disorder,Mouse,-0.3010299956639812,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologist 66,94,2002   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:94   VOLUME:66",,2002.0
338,530,1798,Quetiapine Fumarate,OCCOCCN1CCN(C2=NC3=CC=CC=C3SC3=CC=CC=C23)CC1,Liver disorder,Mouse,-2.855317205195943,Repeated,Oral,"FDA approval package document: Pharmacology Review 020639 Part 02, page:50 PDF 2340k",https://www.pharmapendium.com/browse/fda/Quetiapine Fumarate/9f93629c1e7974400f83b072a3563a8d?reference=50,1997.0
339,531,1801,Quinine Sulfate,C=CC1CN2CCC1CC2C(O)C1=CC=NC2=CC=C(OC)C=C12,Liver disorder,Rat,-2.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 021799/S-000, page:32 PDF 4073k",https://www.pharmapendium.com/browse/fda/Quinine Sulfate/d8d44fcbc384ab756b1af701c59aaa97?reference=32,2005.0
340,532,1803,Quizartinib Dihydrochloride,CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C3=CN4C(=N3)SC3=CC(OCCN5CCOCC5)=CC=C34)C=C2)=NO1,Liver disorder,Rat,-0.4771212547196624,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/CHMP/602286/2019; EMEA/H/C/004468/0000, page:31 PDF 5534k",https://www.pharmapendium.com/browse/ema/Quizartinib Dihydrochloride/e5a1774afc92002d3e3710192a619e0e?reference=31,2019.0
341,533,1804,Rabeprazole Sodium,COCCCOC1=C(C)C(C[S+]([O-])C2=NC3=C(C=CC=C3)N2)=NC=C1,Liver disorder,Rat,-1.7958800173440752,Repeated,Oral,"FDA approval package document: Pharmacology Review 020973/S-000 Part 08, page:6 PDF 602k",https://www.pharmapendium.com/browse/fda/Rabeprazole Sodium/3dfe76675e1ed4e471156a6430dcf569?reference=6,1999.0
342,534,1806,Raloxifene Hydrochloride,O=C(C1=CC=C(OCCN2CCCCC2)C=C1)C1=C(C2=CC=C(O)C=C2)SC2=C1C=CC(O)=C2,Liver disorder,Mouse,-1.505149978319906,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 607775558   ---   DOI:10.1016/j.jconrel.2016.01.016   ISSN:0168-3659   JOURNAL:Journal of Controlled Release   PAGES:186   VOLUME:224,http://dx.doi.org/10.1016/j.jconrel.2016.01.016,2016.0
343,535,1808,Ramelteon,CCC(=O)NCCC1CCC2=CC=C3OCCC3=C21,Liver disorder,Rat,-2.564463979535888,Repeated,Oral,"FDA approval package document: Pharmacology Review 021782/S-000, page:132 PDF 22920k",https://www.pharmapendium.com/browse/fda/Ramelteon/e747eec7ca64f09ae8c52babd18274c4?reference=132,2004.0
344,536,1850,Ranitidine Hydrochloride,CN=C(C[N+](=O)[O-])NCCSCC1=CC=C(CN(C)C)O1,Liver disorder,Rat,-1.414973347970818,Repeated,Oral,Reference from PharmaPendium Published Toxicity: Ranitidin2   ---   JOURNAL:Journal of Toxicological Sciences   PAGES:25   VOLUME:8,,1983.0
345,537,1851,Rasagiline Mesylate,C#CCNC1CCC2=CC=CC=C21,Liver disorder,Rat,-1.230448921378274,Repeated,Oral,"FDA approval package document: Pharmacology Review 021641/S-000 Part 02, page:16 PDF 3944k",https://www.pharmapendium.com/browse/fda/Rasagiline Mesylate/023eb7e29544e727a5e4fed62d4747ff?reference=16,2006.0
346,540,1862,Repaglinide,CCOC1=CC(CC(=O)NC(CC(C)C)C2=CC=CC=C2N2CCCCC2)=CC=C1C(=O)O,Liver disorder,Rat,-1.7781512503836436,Repeated,Oral,"FDA approval package document: Pharmacology Review 020741 Part 01, page:18 PDF 1074k",https://www.pharmapendium.com/browse/fda/Repaglinide/ea3149538361239394bc58a5c18e0410?reference=18,1997.0
347,541,1863,Ribavirin,NC(=O)C1=NN(C2OC(CO)C(O)C2O)C=N1,Liver disorder,Rat,-2.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 020903, page:19 PDF 3578k",https://www.pharmapendium.com/browse/fda/Ribavirin/532e0868cbbe27fc31acf48eb519ab62?reference=19,1998.0
348,542,1864,Riboflavin,CC1=CC2=C(C=C1C)N(CC(O)C(O)C(O)CO)C1=NC(=O)NC(=O)C1=N2,Liver disorder,Mouse,-0.4771212547196624,Repeated,Parenteral,Reference from PharmaPendium Published Toxicity: 604869404   ---   ISSN:1945-0494   JOURNAL:Frontiers in Bioscience - Elite   PAGES:278   VOLUME:7,,2015.0
349,543,1865,Rifabutin,COC1/C=C/OC2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)C1=NC3(CCN(CC(C)C)CC3)N=C12,Liver disorder,Mouse,-2.113943352306837,Repeated,Oral,"FDA approval package document: Pharmacology Review 050689 Part 01, page:6 PDF 2116k",https://www.pharmapendium.com/browse/fda/Rifabutin/472db84a19090a83f7d084e732bc42ee?reference=6,1992.0
350,544,1867,Rifampin,COC1/C=C/OC2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)C(C=NN1CCN(C)CC1)=C2O,Liver disorder,Rat,-1.9834007381805383,Repeated,Oral,"FDA approval package document: Pharmacology Review 050429, page:12 PDF 779k",https://www.pharmapendium.com/browse/fda/Rifampin/2d295e34c21193a090bbc6a49fda335a?reference=12,1971.0
351,545,1875,Rifapentine,COC1/C=C/OC2(C)OC3=C(C2=O)C2=C(C(O)=C3C)C(O)=C(NC(=O)C(C)=CC=CC(C)C(O)C(C)C(O)C(C)C(OC(C)=O)C1C)C(C=NN1CCN(C3CCCC3)CC1)=C2O,Liver disorder,Rat,-1.6020599913279625,Repeated,Oral,"FDA approval package document: Approval Package 021024/S-008 Part 07, page:14 PDF 1264k",https://www.pharmapendium.com/browse/fda/Rifapentine/89ba87985cd8932a924036f811f6c597?reference=14,2009.0
352,546,1880,Rilpivirine Hydrochloride,CC1=CC(C=CC#N)=CC(C)=C1NC1=CC=NC(NC2=CC=C(C#N)C=C2)=N1,Liver disorder,Mouse,-2.230448921378274,Repeated,Oral,"FDA approval package document: Pharmacology Review 202022/S-000 Part 02, page:15 PDF 1062k",https://www.pharmapendium.com/browse/fda/Rilpivirine Hydrochloride/c3ce45a25c02c2155610f40b8001efa7?reference=15,2010.0
353,550,1917,Risedronate Sodium,O=[PH](=O)(O)C(O)(CC1=CC=CN=C1)[PH](=O)(=O)O,Liver disorder,Rat,-0.7781512503836436,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 020835/S-000 Part 01, page:17 PDF 1678k",https://www.pharmapendium.com/browse/fda/Risedronate Sodium/cf4bdffa67b88eb1d528c8e53aa62e5c?reference=17,1998.0
354,552,1927,Ritodrine Hydrochloride,CC(NCCC1=CC=C(O)C=C1)C(O)C1=CC=C(O)C=C1,Liver disorder,Mouse,-1.0791812460476249,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 51768719   ---   DOI:10.1016/j.yrtph.2011.11.011   ISSN:0273-2300   JOURNAL:Regulatory Toxicology and Pharmacology   PAGES:561   VOLUME:62,http://dx.doi.org/10.1016/j.yrtph.2011.11.011,2012.0
355,554,1946,Rivastigmine Tartrate,CCN(C)C(=O)OC1=CC=CC(C(C)N(C)C)=C1,Liver disorder,Mouse,-1.4471580313422192,Repeated,Oral,Reference from PharmaPendium Published Toxicity: E-368883724   ---   DOI:10.1016/j.ijbiomac.2013.04.024   ISSN:0141-8130   JOURNAL:International Journal of Biological Macromolecules   PAGES:72   VOLUME:59,http://dx.doi.org/10.1016/j.ijbiomac.2013.04.024,2013.0
356,555,1947,Romidepsin,CCC1=NC(=O)C2CSSCC/C=C/C(CC(=O)NC(C(C)C)C(=O)N2)OC(=O)C(C(C)C)NC1=O,Liver disorder,Rat,-1.2844307338445196,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 022393/S-000 Part 02, page:4 PDF 3718k",https://www.pharmapendium.com/browse/fda/Romidepsin/49d32e864b13679d8f3d56df31ffbd20?reference=4,2009.0
357,556,1951,Rosiglitazone Maleate,CN(CCOC1=CC=C(CC2=C(O)NC(=O)S2)C=C1)C1=NC=CC=C1,Liver disorder,Rat,-1.1583624920952498,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 368418603   ---   ISSN:0975-8232   JOURNAL:International Journal of Pharmaceutical Sciences and Research   PAGES:2623   VOLUME:3,,2012.0
358,558,1961,Ruboxistaurin,CN(C)CC1CCN2C=C(C3=C(C(=O)NC3=O)C3=CN(CCO1)C1=C3C=CC=C1)C1=C2C=CC=C1,Liver disorder,Rat,-1.6812412373755872,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologist 60,318,2001   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:318   VOLUME:60",,2001.0
359,559,1963,Rutin,CC1OC(OCC2OC(OC3=C(C4=CC(O)=C(O)C=C4)OC4=CC(O)=CC(O)=C4C3=O)C(O)C(O)C2O)C(O)C(O)C1O,Liver disorder,Rat,-0.6989700043360189,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Pharmacological reports 57,84,2005   ---   JOURNAL:Pharmacological Reports   PAGES:84   VOLUME:57",,2005.0
360,560,1964,Ruxolitinib Phosphate,N#CCC(C1CCCC1)N1C=C(C2=C3C=CNC3=NC=N2)C=N1,Liver disorder,Mouse,-1.1760912590556811,Repeated,Oral,"FDA approval package document: Pharmacology Review 202192/S-000 Part 12, page:4 PDF 3671k",https://www.pharmapendium.com/browse/fda/Ruxolitinib Phosphate/60f38f66888de1e9682e47161e6a17c1?reference=4,2011.0
361,562,1973,Sarecycline Hydrochloride,CON(C)CC1=C2CC3CC4C(N(C)C)C(=O)C(C(N)=O)C(=O)C4(O)C(=O)C3C(=O)C2=C(O)C=C1,Liver disorder,Rat,-1.6989700043360187,Repeated,Oral,"FDA approval package document: Approval Package 209521/S-000 Part 03, page:8 PDF 296k",https://www.pharmapendium.com/browse/fda/Sarecycline Hydrochloride/265bb229b872038fbd38dc3c9fa43460?reference=8,2018.0
362,563,1975,Saxagliptin Hydrochloride,N#CC1CC2CC2N1C(=O)C(N)C12CC3CC(CC(O)(C3)C1)C2,Liver disorder,Rat,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Pharmacology Review 022350/S-000 Part 01, page:54 PDF 4836k",https://www.pharmapendium.com/browse/fda/Saxagliptin Hydrochloride/864e532affdf974f4b612c87811175bd?reference=54,2009.0
363,564,1976,Scopolamine,CN1C2CC(OC(=O)C(CO)C3=CC=CC=C3)CC1C1OC12,Liver disorder,Rat,-2.0791812460476247,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 362372038   ---   ISSN:1996-0875   JOURNAL:Journal of Medicinal Plant Research   PAGES:3421   VOLUME:5,,2011.0
364,565,1977,Secnidazole,CC1=NC=C([N+](=O)[O-])N1CC(C)O,Liver disorder,Rat,-3.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 209363/S-000 Part 02, page:18 PDF 4578k",https://www.pharmapendium.com/browse/fda/Secnidazole/8c58c18d9abd157647542f6d21d53fe4?reference=18,2017.0
365,566,1979,Selegiline,C#CCN(C)C(C)CC1=CC=CC=C1,Liver disorder,Mouse,-1.3010299956639813,Repeated,Oral,"FDA approval package document: Pharmacology Review 021336/S-000; 021708/S-000 Part 02, page:10 PDF 6130k",https://www.pharmapendium.com/browse/fda/Selegiline/ce31447bfb184c2777964b49a3787cb5?reference=10,2004.0
366,568,1986,Selexipag,CC(C)N(CCCCOCC(=O)NS(C)(=O)=O)C1=NC(C2=CC=CC=C2)=C(C2=CC=CC=C2)N=C1,Liver disorder,Rat,-2.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 207947/S-000 Part 01, page:35 PDF 13988k",https://www.pharmapendium.com/browse/fda/Selexipag/28813d88547ecbe05d7ca7b004e64861?reference=35,2010.0
367,572,1991,Sildenafil Citrate,CCCC1=NN(C)C2=C1N=C(C1=CC(S(=O)(=O)N3CCN(C)CC3)=CC=C1OCC)NC2=O,Liver disorder,Rat,-1.4522976709946305,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 372585326   ---   DOI:10.3923/ajdd.2013.32.46   ISSN:2150-427X   JOURNAL:American Journal of Drug Discovery and Development   PAGES:198   VOLUME:3,http://dx.doi.org/10.3923/ajdd.2013.32.46,2013.0
368,574,1998,Simeprevir Sodium,COC1=CC=C2C(OC3CC4C(=O)NC5(C(=O)NS(=O)(=O)C6CC6)CC5/C=C\CCCCN(C)C(=O)C4C3)=CC(C3=NC(C(C)C)=CS3)=NC2=C1C,Liver disorder,Mouse,-3.4771212547196626,Repeated,Oral,"FDA approval package document: Pharmacology Review 205123/S-000 Part 06, page:3 PDF 920k",https://www.pharmapendium.com/browse/fda/Simeprevir Sodium/b2ba442045da74f17195baec91c0db6c?reference=3,2013.0
369,575,1999,Simvastatin,CCC(C)(C)C(=O)OC1CC(C)C=C2C=CC(C)C(CCC3CC(O)CC(=O)O3)C21,Liver disorder,Rat,-1.3263358609287514,Repeated,Oral,"FDA approval package document: Approval Package 019766/S-001, S-002, S-003, S-004, S-005, S-006; 019643/S-041, S-007, S-009, S-037, S-010, S-011, S-013, S-021, S-015 Part 03, page:35 PDF 5142k",https://www.pharmapendium.com/browse/fda/Simvastatin/4ac993ac6bc9a9f5555c1ec9ba3e3165?reference=35,1991.0
370,577,2014,Sirolimus,COC1CC2CCC(C)C(O)(O2)C(=O)C(=O)N2CCCCC2C(=O)OC(C(C)CC2CCC(O)C(OC)C2)CC(=O)C(C)=CC(C)C(O)C(OC)C(=O)C(C)CC(C)/C=C/C=C/C=C/1C,Liver disorder,Mouse,-1.2671717284030135,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 605181707   ---   DOI:10.1111/bph.13168   ISSN:0007-1188   JOURNAL:British Journal of Pharmacology   PAGES:3793   VOLUME:172,http://dx.doi.org/10.1111/bph.13168,2015.0
371,580,2029,Sodium Nitrite,O=NO,Liver disorder,Mouse,-0.9030899869919436,Repeated,Oral,Reference from PharmaPendium Published Toxicity: E-53196455   ---   DOI:10.1016/j.etp.2014.05.003   ISSN:0940-2993   JOURNAL:Experimental and Toxicologic Pathology   PAGES:367   VOLUME:66,http://dx.doi.org/10.1016/j.etp.2014.05.003,2014.0
372,581,2034,Solriamfetol Hydrochloride,NC(=O)OCC(N)CC1=CC=CC=C1,Liver disorder,Mouse,-2.130333768495006,Repeated,Oral,"EMA approval document: Public Assessment Report EMA/686622/2019; EMEA/H/C/004893/0000, page:30 PDF 2601k",https://www.pharmapendium.com/browse/ema/Solriamfetol Hydrochloride/5f1a8c7d521a68a1b6dd499ad36bab3c?reference=30,2019.0
373,583,2045,Spirapril Hydrochloride,CCOC(=O)C(CCC1=CC=CC=C1)NC(C)C(=O)N1CC2(CC1C(=O)O)SCCS2,Liver disorder,Rat,-2.7781512503836434,Repeated,Oral,"FDA approval package document: Pharmacology Review 020240 Part 03, page:4 PDF 797k",https://www.pharmapendium.com/browse/fda/Spirapril Hydrochloride/38ba58bbd567d14297f7eaa20493bf23?reference=4,1994.0
374,584,2046,Spironolactone,CC(=O)SC1C=C2CC(=O)CCC2(C)C2CCC3(C)C(CCC34CCC(=O)O4)C12,Liver disorder,Mouse,-0.4771212547196624,Repeated,Intraperitoneal,"Reference from PharmaPendium Published Toxicity: Toxicologist 90,374,2006   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:374   VOLUME:90",,2006.0
375,585,2047,Stanozolol,CC12CC3=CNN=C3CC1CCC1C2CCC2(C)C1CCC2(C)O,Liver disorder,Rat,-1.4471580313422192,Repeated,Subcutaneous,Reference from PharmaPendium Published Toxicity: 621973976   ---   DOI:10.3892/ijmm.2018.3644   ISSN:1791-244X   JOURNAL:International Journal of Molecular Medicine   PAGES:405   VOLUME:42,http://dx.doi.org/10.3892/ijmm.2018.3644,2018.0
376,586,2048,Stavudine,CC1=CN(C2C=CC(CO)O2)C(=O)NC1=O,Liver disorder,Mouse,-0.6020599913279624,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Journal of Pharmacology and Experimental Therapeutics 297,516,2001   ---   JOURNAL:Journal of Pharmacology and Experimental Therapeutics   PAGES:516   VOLUME:297",,2001.0
377,587,2053,Stiripentol,CC(C)(C)C(O)/C=C/C1=CC=C2OCOC2=C1,Liver disorder,Rat,-2.322219294733919,Repeated,Oral,"FDA approval package document: Pharmacology Review 206709/S-000; 207223/S-000 Part 02, page:35 PDF 4467k",https://www.pharmapendium.com/browse/fda/Stiripentol/83a501b83abbfc2c7987f8eb53ab65bf?reference=35,2018.0
378,588,2059,Succimer,O=C(O)C(S)C(S)C(=O)O,Liver disorder,Rat,-1.1760912590556811,Repeated,Intraperitoneal,"Reference from PharmaPendium Published Toxicity: food and chemical toxicology 39,1029,2001   ---   DOI:10.1016/S0278-6915(01)00046-1   ISSN:0278-6915   JOURNAL:Food and Chemical Toxicology   PAGES:1029   VOLUME:39",http://dx.doi.org/10.1016/S0278-6915(01)00046-1,2001.0
379,589,2060,Sulfadimethoxine,COC1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=NC(OC)=N1,Liver disorder,Rat,-4.380211241711606,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Gigiena i Sanitariya 40(9),115,1975   ---   ISSN:0016-9900   JOURNAL:Gigiena i Sanitariya   PAGES:115   VOLUME:40",,1975.0
380,590,2061,Sulfasalazine,O=C(O)C1=C(O)C=CC(N=NC2=CC=C(S(=O)(=O)NC3=CC=CC=N3)C=C2)=C1,Liver disorder,Mouse,-2.829303772831025,Repeated,Oral,"FDA approval package document: Pharmacology Review 007073, page:9 PDF 784k",https://www.pharmapendium.com/browse/fda/Sulfasalazine/2628d3673f6496577c84a100bf3448ad?reference=9,1996.0
381,591,2062,Sulfisoxazole,CC1=NOC(NS(=O)(=O)C2=CC=C(N)C=C2)=C1C,Liver disorder,Mouse,-1.414973347970818,Repeated,Skin,"Reference from PharmaPendium Published Toxicity: Toxicologist 60,278,2001   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:278   VOLUME:60",,2001.0
382,592,2064,Sulfisoxazole Acetyl,CC(=O)N(C1=C(C)C(C)=NO1)S(=O)(=O)C1=CC=C(N)C=C1,Liver disorder,Mouse,-1.414973347970818,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toxicologist 60,278,2001   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:278   VOLUME:60",,2001.0
383,594,2068,Sumatriptan Succinate,CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1,Liver disorder,Rat,-1.635986111800833,Repeated,Inhalation,"FDA approval package document: Approval Package 020626 Part 03, page:45 PDF 10057k",https://www.pharmapendium.com/browse/fda/Sumatriptan Succinate/fa58bff99dc92f0b99b39ee4190f1d2f?reference=45,1997.0
384,597,2082,Tacrolimus,C=CCC1=CC(C)CC(C)CC(OC)C2OC(O)(C(=O)C(=O)N3CCCCC3C(=O)OC(/C(C)=C/C3CCC(O)C(OC)C3)C(C)C(O)CC1=O)C(C)CC2OC,Liver disorder,Rat,-1.166331421766525,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 606130949   ---   DOI:10.1007/s13206-015-9209-8   ISSN:1976-0280   JOURNAL:Biochip Journal   PAGES:202   VOLUME:9,http://dx.doi.org/10.1007/s13206-015-9209-8,2015.0
385,598,2085,Tadalafil,CN1CC(=O)N2C(CC3=C(NC4=C3C=CC=C4)C2C2=CC=C3OCOC3=C2)C1=O,Liver disorder,Rabbit,-2.45484486000851,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 2008597133   ---   DOI:10.1371/journal.pone.0241509   ISSN:1932-6203   JOURNAL:PLoS ONE   PAGES:e0241509   VOLUME:15,http://dx.doi.org/10.1371/journal.pone.0241509,2020.0
386,599,2086,Tafamidis Meglumine,CNCC(O)C(O)C(O)C(O)CO,Liver disorder,Mouse,-1.7634279935629371,Repeated,Oral,"FDA approval package document: Pharmacology Review 021199/S-000, page:30 PDF 7828k",https://www.pharmapendium.com/browse/fda/Tafamidis Meglumine/545d267566ccb8c48ebf2151cded7963?reference=30,2019.0
387,601,2092,Tamoxifen Citrate,CC/C(=C(\C1=CC=CC=C1)C1=CC=C(OCCN(C)C)C=C1)C1=CC=CC=C1,Liver disorder,Rat,-1.5314789170422551,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Pharmacological reports 58,435,2006   ---   JOURNAL:Pharmacological Reports   PAGES:435   VOLUME:58",,2006.0
388,602,2094,Tamsulosin Hydrochloride,CCOC1=CC=CC=C1OCCNC(C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1,Liver disorder,Rat,-0.7781512503836436,Repeated,Oral,"FDA approval package document: Approval Package 020579/S-000, page:185 PDF 8915k",https://www.pharmapendium.com/browse/fda/Tamsulosin Hydrochloride/4d520d656e6071d5a0b8a892b782821d?reference=185,1997.0
389,603,2095,Tapentadol Hydrochloride,CCC(C1=CC(O)=CC=C1)C(C)CN(C)C,Liver disorder,Rat,-2.3521825181113627,Repeated,Oral,"FDA approval package document: Pharmacology Review 022304/S-000 Part 02, page:9 PDF 6376k",https://www.pharmapendium.com/browse/fda/Tapentadol Hydrochloride/0ad47c11902adf65b04e5c9c7b4f4679?reference=9,2008.0
390,604,2097,Tasimelteon,CCC(=O)NCC1CC1C1=C2CCOC2=CC=C1,Liver disorder,Rat,-2.406540180433955,Repeated,Oral,"EMA approval document: Assessment Report EMA/CHMP/601383/2014; EMEA/H/C/003870/0000, page:20 PDF 1931k",https://www.pharmapendium.com/browse/ema/Tasimelteon/a851a060b7cbb6ae316f3471abab8910?reference=20,2015.0
391,605,2107,Tazarotene,CCOC(=O)C1=CN=C(C#CC2=CC3=C(C=C2)SCCC3(C)C)C=C1,Liver disorder,Rat,-1.6989700043360187,Repeated,Skin,"FDA approval package document: Pharmacology Review 202428/S-000, page:26 PDF 4216k",https://www.pharmapendium.com/browse/fda/Tazarotene/40fcde14fd2930e0dd10357ce04f9313?reference=26,2011.0
392,608,2123,Telaprevir,CCCC(NC(=O)C1C2CCCC2CN1C(=O)C(NC(=O)C(NC(=O)C1=NC=CN=C1)C1CCCCC1)C(C)(C)C)C(=O)C(=O)NC1CC1,Liver disorder,Rat,-3.0,Repeated,Oral,"EMA approval document: Assessment Report EMEA/H/C/002313; EMA/CHMP/475470/2011, page:21 PDF 4313k",https://www.pharmapendium.com/browse/ema/Telaprevir/1f807b717a2c2206ac3ccbf3f4296e6b?reference=21,2011.0
393,610,2125,Telithromycin,CCC1OC(=O)C(C)C(=O)C(C)C(OC2OC(C)CC(N(C)C)C2O)C(C)(OC)CC(C)C(=O)C(C)C2N(CCCCN3C=NC(C4=CN=CC=C4)=C3)C(=O)OC12C,Liver disorder,Rat,-0.4259687322722812,Repeated,Oral,"FDA approval package document: Approval Package 021144/S-012, page:58 PDF 657k",https://www.pharmapendium.com/browse/fda/Telithromycin/3525544120b4529175fd8596ec3552c0?reference=58,2007.0
394,611,2128,Telmisartan,CCCC1=NC2=C(C)C=C(C3=NC4=CC=CC=C4N3C)C=C2N1CC1=CC=C(C2=CC=CC=C2C(=O)O)C=C1,Liver disorder,Rat,-2.0498638138403336,Repeated,Oral,"FDA approval package document: Pharmacology Review 020850/S-000 Part 02, page:36 PDF 1862k",https://www.pharmapendium.com/browse/fda/Telmisartan/2ac0fc15a5c4dc8bfda5f80bd0cf7f06?reference=36,1998.0
395,613,2136,Tenofovir Disoproxil Fumarate,CC(C)OC(=O)OCOP(=O)(COC(C)CN1C=NC2=C1N=CN=C2N)OCOC(=O)OC(C)C,Liver disorder,Mouse,-1.9590413923210936,Repeated,Intragastric,Reference from PharmaPendium Published Toxicity: 602531515   ---   DOI:10.1177/1091581814565669   ISSN:1091-5818   JOURNAL:International Journal of Toxicology   PAGES:4   VOLUME:34,http://dx.doi.org/10.1177/1091581814565669,2015.0
396,614,2137,Terazosin Hydrochloride,COC1=CC2=NC(N3CCN(C(=O)C4CCCO4)CC3)=NC(N)=C2C=C1OC,Liver disorder,Rat,-2.1903316981702914,Repeated,Oral,"FDA approval package document: Approval Package 019057/S-006, S-002, S-001, S-008, S-003, S-004, S-009, S-011; 020347/S-002 Part 07, page:9 PDF 6703k",https://www.pharmapendium.com/browse/fda/Terazosin Hydrochloride/f8f8aaf15a492f3ec032e98041190442?reference=9,1988.0
397,615,2139,Terbinafine Hydrochloride,CN(C/C=C/C#CC(C)(C)C)CC1=C2C=CC=CC2=CC=C1,Liver disorder,Rat,-1.7732987475892317,Repeated,Oral,"FDA approval package document: Pharmacology Review 020539, page:11 PDF 1350k",https://www.pharmapendium.com/browse/fda/Terbinafine Hydrochloride/288d38b049c2019ed95b6a9296e158f2?reference=11,1991.0
398,616,2145,Terbutaline Sulfate,CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1,Liver disorder,Rat,-0.6020599913279624,Repeated,Subcutaneous,"Reference from PharmaPendium Published Toxicity: Toxicologist 72,177,2003   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:177   VOLUME:72",,2003.0
399,619,2155,Testosterone,CC12CCC(=O)C=C1CCC1C2CCC2(C)C(O)CCC12,Liver disorder,Mouse,-0.8750612633917001,Repeated,Subcutaneous,Reference from PharmaPendium Published Toxicity: 52470590   ---   DOI:10.1111/acel.12052   ISSN:1474-9718   JOURNAL:Aging Cell   PAGES:280   VOLUME:12,http://dx.doi.org/10.1111/acel.12052,2013.0
400,621,2158,Thalidomide,O=C1CCC(N2C(=O)C3=CC=CC=C3C2=O)C(=O)N1,Liver disorder,Rabbit,-2.6989700043360187,Repeated,Oral,"FDA approval package document: Pharmacology Review 021430/S-000, page:17 PDF 2111k",https://www.pharmapendium.com/browse/fda/Thalidomide/9012fed3c6bf13625588237a3d59347e?reference=17,2005.0
401,622,2159,Theophylline,CN1C(=O)C2=C(N=CN2)N(C)C1=O,Liver disorder,Rat,-1.2430380486862944,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Fundamental and Applied Toxicology 14,167,1990   ---   DOI:10.1016/0272-0590(90)90242-C   ISSN:0272-0590   JOURNAL:Fundamental and Applied Toxicology   PAGES:167   VOLUME:14",http://dx.doi.org/10.1016/0272-0590(90)90242-C,1990.0
402,623,2161,Thiabendazole,C1=CC=C2NC(C3=CSC=N3)=NC2=C1,Liver disorder,Mouse,-1.1613680022349748,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Food and Chemical Toxicology 34,709,1996   ---   DOI:10.1016/0278-6915(96)00035-X   ISSN:0278-6915   JOURNAL:Food and Chemical Toxicology   PAGES:709   VOLUME:34",http://dx.doi.org/10.1016/0278-6915(96)00035-X,1996.0
403,625,2166,Tinidazole,CCS(=O)(=O)CCN1C([N+](=O)[O-])=CN=C1C,Liver disorder,Rat,-2.865301426102544,Repeated,Oral,"FDA approval package document: Pharmacology Review 021618/S-000; 021681/S-000; 021682/S-000, page:13 PDF 754k",https://www.pharmapendium.com/browse/fda/Tinidazole/1115201a094112e31bf6e32b36b87d7b?reference=13,2004.0
404,626,2169,Tiopronin,CC(S)C(=O)NCC(=O)O,Liver disorder,Rat,-2.6989700043360187,Repeated,Intraperitoneal,"FDA approval package document: Approval Package 019569 Part 01, page:57 PDF 4355k",https://www.pharmapendium.com/browse/fda/Tiopronin/f792a895f091b57bdf5f2f4a08f228e4?reference=57,1986.0
405,627,2170,Tiotropium Bromide,C[N+]1(C)C2CC(OC(=O)C(O)(C3=CC=CS3)C3=CC=CS3)CC1C1OC12,Liver disorder,Rat,-1.0071785846271235,Repeated,Oral,"FDA approval package document: Pharmacology Review 021395/S-000 Part 04, page:3 PDF 1337k",https://www.pharmapendium.com/browse/fda/Tiotropium Bromide/ef9984eeaae79affeaa10118d395ad2b?reference=3,2002.0
406,630,2188,Tobramycin,NCC1OC(OC2C(N)CC(N)C(OC3OC(CO)C(O)C(N)C3O)C2O)C(N)CC1O,Liver disorder,Rat,-1.6720978579357175,Repeated,Inhalation,"FDA approval package document: Approval Package 050753/S-000 Part 02, page:7 PDF 1665k",https://www.pharmapendium.com/browse/fda/Tobramycin/3dd59f4e45a6270ec726a6d93d62aa21?reference=7,1997.0
407,631,2190,Tofacitinib Citrate,CC1CCN(C(=O)CC#N)CC1N(C)C1=C2C=CNC2=NC=N1,Liver disorder,Rat,-1.960100647680116,Repeated,Oral,"FDA approval package document: Pharmacology Review 203214/S-000 Part 08, page:47 PDF 6102k",https://www.pharmapendium.com/browse/fda/Tofacitinib Citrate/f6e16bee23f174d5f9e5b6367893eed3?reference=47,2012.0
408,632,2201,Tolcapone,CC1=CC=C(C(=O)C2=CC(O)=C(O)C([N+](=O)[O-])=C2)C=C1,Liver disorder,Rat,-1.1903316981702914,Repeated,,"Reference from PharmaPendium Published Toxicity: Toxicologist -,334,2009   ---   ISSN:0731-9193   JOURNAL:Toxicologist   PAGES:334",,2009.0
409,633,2203,Tolterodine Tartrate,CC1=CC=C(O)C(C(CCN(C(C)C)C(C)C)C2=CC=CC=C2)=C1,Liver disorder,Mouse,-1.484299839346786,Repeated,Oral,"FDA approval package document: Pharmacology Review 020771/S-000 Part 02, page:3 PDF 964k",https://www.pharmapendium.com/browse/fda/Tolterodine Tartrate/0ba6d187f19f93d93445d86d29ff519a?reference=3,1997.0
410,635,2209,Topiramate,CC1(C)OC2COC3(COS(N)(=O)=O)OC(C)(C)OC3C2O1,Liver disorder,Rat,-1.7853298350107671,Repeated,Oral,"FDA approval package document: Pharmacology Review 020505, page:40 PDF 2630k",https://www.pharmapendium.com/browse/fda/Topiramate/6f28acab754377cc076dfbd2a6bf6ba9?reference=40,1995.0
411,636,2224,Tramadol Hydrochloride,COC1=CC(C2(O)CCCCC2CN(C)C)=CC=C1,Liver disorder,Mouse,-0.0,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 631867417   ---   DOI:10.36295/ASRO.2020.23219   ISSN:1755-6783   JOURNAL:Annals of Tropical Medicine and Public Health   PAGES:128   VOLUME:23,http://dx.doi.org/10.36295/ASRO.2020.23219,2020.0
412,638,2232,Treprostinil Diolamine,CCCCCC(O)CCC1C(O)CC2CC3=C(OCC(=O)O)C=CC=C3CC21,Liver disorder,Mouse,-1.0,Repeated,Oral,"FDA approval package document: Pharmacology Review 203496/S-000 Part 03, page:34 PDF 9686k",https://www.pharmapendium.com/browse/fda/Treprostinil Diolamine/f83e432762117aeadba44bfea378a798?reference=34,2012.0
413,639,2233,Treprostinil Sodium,CCCCCC(O)CCC1C(O)CC2CC3=C(C=CC=C3OCC(=O)O)CC21,Liver disorder,Rat,-8.83378437465648,Repeated,Inhalation,"FDA approval package document: Pharmacology Review 022387/S-000, page:14 PDF 1329k",https://www.pharmapendium.com/browse/fda/Treprostinil Sodium/e6609c1cba7fb378fb72047b302a60dd?reference=14,2009.0
414,640,2235,Tretinoin,CC(C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)=CC(=O)O,Liver disorder,Rat,-0.8325089127062363,Repeated,Oral,"FDA approval package document: Pharmacology Review 019963, page:19 PDF 729k",https://www.pharmapendium.com/browse/fda/Tretinoin/cf417333aae6a59c41cd6f24dd8d2185?reference=19,1989.0
415,643,2275,Trifarotene,CC(C)(C)C1=CC(C2=CC(C3=CC=C(C(=O)O)C=C3)=CC=C2OCCO)=CC=C1N1CCCC1,Liver disorder,Rat,-0.5440680443502757,Repeated,Oral,"FDA approval package document: Approval Package 211527/S-000 Part 06, page:11 PDF 2162k",https://www.pharmapendium.com/browse/fda/Trifarotene/9aa4d08f99ceb910de6553d3cdef841a?reference=11,2019.0
416,644,2277,Trimethobenzamide Hydrochloride,COC1=CC(C(=O)NCC2=CC=C(OCCN(C)C)C=C2)=CC(OC)=C1OC,Liver disorder,Rat,-0.6989700043360189,Repeated,Intramuscular,Reference from PharmaPendium Published Toxicity: 362549560   ---   DOI:10.3109/14767058.2010.536867   ISSN:1476-7058   JOURNAL:Journal of Maternal-Fetal and Neonatal Medicine   PAGES:1176   VOLUME:24,http://dx.doi.org/10.3109/14767058.2010.536867,2011.0
417,645,2278,Troglitazone,CC1=C(O)C(C)=C2CCC(C)(COC3=CC=C(CC4=C(O)NC(=O)S4)C=C3)OC2=C1C,Liver disorder,Rat,-0.8760584957056488,Repeated,Unreported,Reference from PharmaPendium Published Toxicity: 51322613   ---   DOI:10.1016/j.taap.2011.01.021   ISSN:0041-008X   JOURNAL:Toxicology and Applied Pharmacology   PAGES:85   VOLUME:252,http://dx.doi.org/10.1016/j.taap.2011.01.021,2011.0
418,646,2308,Tucatinib,CC1=CC(NC2=NC=NC3=CC=C(N=C4NC(C)(C)CO4)C=C23)=CC=C1OC1=CC2=NC=NN2C=C1,Liver disorder,Rat,-1.5185139398778875,Repeated,Oral,"FDA approval package document: Approval Package 213411/S-000 Part 03, page:22 PDF 716k",https://www.pharmapendium.com/browse/fda/Tucatinib/ef696b946e4eeb2c99883f4f117aef7c?reference=22,2020.0
419,647,2310,Ulipristal Acetate,CC(=O)OC1(C(C)=O)CCC2C3=C(C4=C(CC3)CC(=O)CC4)C(C3=CC=C(N(C)C)C=C3)CC21C,Liver disorder,Rat,-1.6020599913279625,Repeated,Oral,"EMA approval document: Assessment Report EMA/486902/2018; EMEA/H/C/002041//0000, page:22 PDF 1786k",https://www.pharmapendium.com/browse/ema/Ulipristal Acetate/12269073416197a643ca22f7c384c714?reference=22,2011.0
420,648,2314,Unoprostone Isopropyl,CCCCCCCC(=O)CCC1C(O)CC(O)C1C/C=C\CCCC(=O)OC(C)C,Liver disorder,Rat,-2.6532125137753435,Repeated,Oral,"FDA approval package document: Pharmacology Review 021214 Part 01, page:77 PDF 3534k",https://www.pharmapendium.com/browse/fda/Unoprostone Isopropyl/4857d3dc38c041c253c003844dd17da5?reference=77,2000.0
422,650,2320,Valproate Sodium,CCCC(CCC)C(=O)O,Liver disorder,Rat,-2.0322733058555174,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 020593, page:6 PDF 890k",https://www.pharmapendium.com/browse/fda/Valproate Sodium/5540ea79640a84fc117d05730a4a576d?reference=6,1995.0
424,652,2329,Valsartan,CCCCC(=O)N(CC1=CC=C(C2=CC=CC=C2C2=NNN=N2)C=C1)C(C(=O)O)C(C)C,Liver disorder,Rat,-2.439332693830263,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 020665 Part 01, page:66 PDF 2728k",https://www.pharmapendium.com/browse/fda/Valsartan/929c2967baac516b796bd4c6fdf5cc2c?reference=66,1995.0
425,655,2335,Vardenafil Hydrochloride,CCCC1=NC(C)=C2C(=O)NC(C3=C(OCC)C=CC(S(=O)(=O)N4CCN(CC)CC4)=C3)=NN12,Liver disorder,Rabbit,-2.45484486000851,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 2008597133   ---   DOI:10.1371/journal.pone.0241509   ISSN:1932-6203   JOURNAL:PLoS ONE   PAGES:e0241509   VOLUME:15,http://dx.doi.org/10.1371/journal.pone.0241509,2020.0
426,656,2336,Varenicline Tartrate,C1=CN=C2C=C3C(=CC2=N1)C1CNCC3C1,Liver disorder,Rat,-0.7403626894942439,Repeated,Oral,"FDA approval package document: Pharmacology Review 021928/S-000 Part 02, page:79 PDF 5452k",https://www.pharmapendium.com/browse/fda/Varenicline Tartrate/39576e5a6c086fa0cd3135c24d73bf80?reference=79,2006.0
427,658,2339,Venlafaxine Hydrochloride,COC1=CC=C(C(CN(C)C)C2(O)CCCCC2)C=C1,Liver disorder,Rat,-2.342422680822206,Repeated,Oral,"FDA approval package document: Approval Package 020151; 020527 Part 06, page:57 PDF 6652k",https://www.pharmapendium.com/browse/fda/Venlafaxine Hydrochloride/0b036460439562ccde4cec55df0c1d3f?reference=57,1993.0
428,659,2341,Verapamil Hydrochloride,COC1=CC=C(CCN(C)CCCC(C#N)(C2=CC=C(OC)C(OC)=C2)C(C)C)C=C1OC,Liver disorder,Rat,-1.414973347970818,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Toksikologicheskii Vestnik (2),37,1996   ---   ISSN:0869-7922   JOURNAL:Toksikologicheskii Vestnik   PAGES:37",,1996.0
429,660,2342,Vibegron,O=C(NC1=CC=C(CC2CCC(C(O)C3=CC=CC=C3)N2)C=C1)C1CCC2=NC=CC(=O)N21,Liver disorder,Rat,-2.4771212547196626,Repeated,Oral,"FDA approval package document: Pharmacology Review 213006/S-000 Part 02, page:64 PDF 11377k",https://www.pharmapendium.com/browse/fda/Vibegron/bb3b13290d2f9cd4493e441be6087fca?reference=64,2020.0
430,661,2343,Vidarabine,NC1=NC=NC2=C1N=CN2C1OC(CO)C(O)C1O,Liver disorder,Mouse,-2.5289167002776547,Repeated,Oral,"FDA approval package document: Approval Package 050486 Part 03, page:4 PDF 1057k",https://www.pharmapendium.com/browse/fda/Vidarabine/f71db8956ee464c258622939d784a450?reference=4,1976.0
431,662,2348,Vigabatrin,C=CC(N)CCC(=O)O,Liver disorder,Rat,-0.6020599913279624,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 51465034   ---   DOI:10.1016/j.neuro.2011.03.014   ISSN:0161-813X   JOURNAL:NeuroToxicology   PAGES:963   VOLUME:32,http://dx.doi.org/10.1016/j.neuro.2011.03.014,2011.0
432,663,2349,Vilazodone Hydrochloride,N#CC1=CC=C2NC=C(CCCCN3CCN(C4=CC5=C(C=C4)C=C(C(N)=O)O5)CC3)C2=C1,Liver disorder,Rat,-1.9420080530223127,Repeated,Oral,"FDA approval package document: Pharmacology Review 022567/S-000 Part 05, page:17 PDF 990k",https://www.pharmapendium.com/browse/fda/Vilazodone Hydrochloride/dbab2d8350ab50653c23ef6b4baae814?reference=17,2010.0
433,664,2351,Vinorelbine Tartrate,CCC1=CC2CN1CCC1=C(NC3=CC=CC=C13)C(C(=O)OC)(C1=C(OC)C=C3C(=C1)C14CCN5CC=CC(CC)(C(OC(C)=O)C(O)(C(=O)OC)C1N3C)C54)C2,Liver disorder,Rat,-0.8239087409443188,Repeated,Intravenous,"FDA approval package document: Pharmacology Review 020388 Part 02, page:7 PDF 1241k",https://www.pharmapendium.com/browse/fda/Vinorelbine Tartrate/664b8ac32ed13663aa956933bf9b61b7?reference=7,1993.0
434,665,2364,Vitamin A,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,Liver disorder,Rat,-0.7481880270062004,Repeated,Oral,Reference from PharmaPendium Published Toxicity: 51718428   ---   DOI:10.1016/j.foodchem.2011.10.082   ISSN:0308-8146   JOURNAL:Food Chemistry   PAGES:311   VOLUME:132,http://dx.doi.org/10.1016/j.foodchem.2011.10.082,2012.0
435,666,2370,Vitamin E,CC1=C(O)C(C)=C2CCC(C)(CCCC(C)CCCC(C)CCCC(C)C)OC2=C1C,Liver disorder,Rat,-0.3010299956639812,Repeated,Oral,"Reference from PharmaPendium Published Toxicity: Iranian journal of pharmacology & therapeutics 6,63,2007   ---   JOURNAL:Iranian Journal of Pharmacology and Therapeutics   PAGES:63   VOLUME:6",,2007.0
436,667,2371,Voclosporin,C=C/C=C/CC(C)C(O)C1C(=O)NC(CC)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,Liver disorder,Rat,-0.9420080530223132,Repeated,Oral,"FDA approval package document: Approval Package 213716/S-000 Part 02, page:15 PDF 517k",https://www.pharmapendium.com/browse/fda/Voclosporin/b13979e3faa6bd886ebb4ba54fb7b677?reference=15,2010.0
437,668,2376,Volanesorsen,COCCOC1C(O)C(COP(=O)(S)OC2C(COP(=O)(S)OC3C(COP(=O)(S)OC4C(COP(=O)(S)OC5C(COP(=O)(S)OC6CC(N7C=C(C)C(N)=NC7=O)OC6COP(=O)(S)OC6CC(N7C=NC8=C7N=C(N)NC8=O)OC6COP(=O)(S)OC6CC(N7C=NC8=C7N=CN=C8N)OC6COP(=O)(S)OC6CC(N7C=C(C)C(N)=NC7=O)OC6COP(=O)(S)OC6CC(N7C=C(C)C(N)=NC7=O)OC6COP(=O)(S)OC6CC(N7C=C(C)C(=O)NC7=O)OC6COP(=O)(S)OC6CC(N7C=NC8=C7N=C(N)NC8=O)OC6COP(=O)(S)OC6CC(N7C=C(C)C(=O)NC7=O)OC6COP(=O)(S)OC6CC(N7C=C(C)C(=O)NC7=O)OC6COP(=O)(S)OC6CC(N7C=C(C)C(N)=NC7=O)OC6COP(=O)(S)OC6C(COP(=O)(S)OC7C(COP(=O)(S)OC8C(COP(=O)(S)OC9C(COP(=O)(S)OC%10C(CO)OC(N%11C=NC%12=C%11N=CN=C%12N)C%10OCCOC)OC(N%10C=NC%11=C%10N=C(N)NC%11=O)C9OCCOC)OC(N9C=C(C)C(N)=NC9=O)C8OCCOC)OC(N8C=C(C)C(=O)NC8=O)C7OCCOC)OC(N7C=C(C)C(=O)NC7=O)C6OCCOC)OC(N6C=C(C)C(=O)NC6=O)C5OCCOC)OC(N5C=C(C)C(=O)NC5=O)C4OCCOC)OC(N4C=C(C)C(=O)NC4=O)C3OCCOC)OC(N3C=NC4=C3N=CN=C4N)C2OCCOC)OC1N1C=C(C)C(=O)NC1=O,Liver disorder,Rat,-1.1760912590556811,Repeated,Subcutaneous,"EMA approval document: Public Assessment Report EMA/180717/2019; EMEA/H/C/004538/0000, page:35 PDF 2540k",https://www.pharmapendium.com/browse/ema/Volanesorsen/ffed6226a16c8c31a83ba8bf3f4abd39?reference=35,2019.0
438,670,2380,Vorinostat,O=C(CCCCCCC(O)=NO)NC1=CC=CC=C1,Liver disorder,Rat,-2.1760912590556813,Repeated,Oral,"FDA approval package document: Pharmacology Review 021991/S-000, page:56 PDF 5280k",https://www.pharmapendium.com/browse/fda/Vorinostat/0dd5aa1e25886415619058284deb3481?reference=56,2006.0
439,671,2382,Vortioxetine Hydrobromide,CC1=CC(C)=C(SC2=CC=CC=C2N2CCNCC2)C=C1,Liver disorder,Rat,-1.8260748027008264,Repeated,Oral,"FDA approval package document: Pharmacology Review 204447/S-000 Part 03, page:29 PDF 5501k",https://www.pharmapendium.com/browse/fda/Vortioxetine Hydrobromide/d95155697bd84b1d4ff2ac02ef4655aa?reference=29,2013.0
440,672,2394,Voxelotor,CC(C)N1N=CC=C1C1=NC=CC=C1COC1=C(C=O)C(O)=CC=C1,Liver disorder,Rat,-2.27382771281152,Repeated,Oral,"FDA approval package document: Approval Package 213137/S-000 Part 03, page:3 PDF 474k",https://www.pharmapendium.com/browse/fda/Voxelotor/2538a5f060b6aa637ef7aec013e46c87?reference=3,2019.0
441,673,2401,Zafirlukast,COC1=CC(C(=O)NS(=O)(=O)C2=CC=CC=C2C)=CC=C1CC1=CN(C)C2=C1C=C(NC(=O)OC1CCCC1)C=C2,Liver disorder,Rat,-2.6020599913279625,Repeated,Oral,"FDA approval package document: Pharmacology Review 020547, page:17 PDF 601k",https://www.pharmapendium.com/browse/fda/Zafirlukast/f8c2d7162291d2dd386c52438f96c39c?reference=17,1996.0
442,674,2402,Zalcitabine,NC1=NC(=O)N(C2CCC(CO)O2)C=C1,Liver disorder,Rat,-2.5118833609788744,Repeated,Oral,"FDA approval package document: Pharmacology Review 020199 Part 01, page:9 PDF 969k",https://www.pharmapendium.com/browse/fda/Zalcitabine/599e3763b8ebc97cbdb6e0b995bcbe24?reference=9,1992.0
443,675,2404,Zaleplon,CCN(C(C)=O)C1=CC=CC(C2=CC=NC3=C(C#N)C=NN23)=C1,Liver disorder,Rat,-1.8915881367649727,Repeated,Oral,"FDA approval package document: Pharmacology Review 020859/S-000 Part 04, page:6 PDF 1652k",https://www.pharmapendium.com/browse/fda/Zaleplon/a6e4ad838665dd61983c05ac761968f6?reference=6,
444,676,2437,Zidovudine,CC1=CN(C2CC(N=[N+]=[N-])C(CO)O2)C(=O)NC1=O,Liver disorder,Mouse,-0.8061799739838872,Repeated,Intraperitoneal,Reference from PharmaPendium Published Toxicity: 604820658   ---   DOI:10.1371/journal.pone.0085637   ISSN:1932-6203   JOURNAL:PLoS ONE   VOLUME:9,http://dx.doi.org/10.1371/journal.pone.0085637,2014.0
445,677,2443,Zileuton,CC(C1=CC2=CC=CC=C2S1)N(O)C(N)=O,Liver disorder,Rat,-1.977723605288848,Repeated,Oral,"FDA approval package document: Pharmacology Review 020471, page:10 PDF 1131k",https://www.pharmapendium.com/browse/fda/Zileuton/3353c8ceba6ddd448837e190a8dc33e4?reference=10,1990.0
446,680,2461,Zonisamide,NS(=O)(=O)CC1=NOC2=CC=CC=C12,Liver disorder,Rat,-1.7781512503836436,Repeated,Oral,"EMA approval document: Assessment Report EMA/470045/2013; EMEA/H/C/000577/II/0065, page:4 PDF 1046k",https://www.pharmapendium.com/browse/ema/Zonisamide/a7acf6027fd446290de64f99269548e6?reference=4,2013.0
